Wayne State University
Wayne State University Dissertations

1-1-2011

Reinforced chitosan-based heart valve scaffold and
utility of bone marrow-derived mesenchymal stem
cells for cardiovascular tissue engineering
Mohammad Z. Albanna
Wayne State University

Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations
Part of the Biomedical Engineering and Bioengineering Commons, Chemical Engineering
Commons, and the Materials Science and Engineering Commons
Recommended Citation
Albanna, Mohammad Z., "Reinforced chitosan-based heart valve scaffold and utility of bone marrow-derived mesenchymal stem cells
for cardiovascular tissue engineering" (2011). Wayne State University Dissertations. Paper 230.

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.

REINFORCED CHITOSAN-BASED HEART VALVE SCAFFOLD AND UTILITY
OF BONE MARROW-DERIVED MESENCHYMAL STEM CELLS FOR
CARDIOVASCULAR TISSUE ENGINEERING

by
MOHAMMAD ZAKI ALBANNA
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY
2011
MAJOR: BIOMEDICAL ENGINEERING
Approved by:

Advisor

Date

DEDICATION

Dedicated to Mom, Ahmad, Ruba and Layann……..

ii

ACKNOWLEDGMENTS
The time has come when I must acknowledge those who have affected my life so
greatly that this dissertation could not have been possible without them. Although there
are far too many to mention, I must pay special tribute to a few.
First, and foremost, I thank God Almighty for all the blessings he has bestowed upon
me.
I must thank my queen Ruba and my little princess Layann. You both have
touched the very depths of my soul. My love for you is eternal and unconditional. To my
parents, Dr. Zaki and Mrs. Mussarah Sweidan: without you none of this could have
been possible. To My brother Dr. Ahmad Albanna, you always stood beside me and
helped me through every step of my education. My little sisters‐Esra and Tasneem: I
want to thank you for all your calls and prayers. God could not have blessed me with a
better family. To my parents in law, Azmi and Fathia, and their family, thanks all for you
support.
I must also thank my advisors and mentors, Professors Howard W. T. Matthew
and Henry L. Walter III: Without your patience, help, and faith in my abilities, I would not
have finished this dissertation. You have guided me and given me inspiration to
continue with my education. I also extend my sincere gratitude to Professors Michele
Grimm and Pamela VandeVord, my committee members, for their patience and
research support during my Ph.D. research. Moreover, infinite thanks to Dr. Therese
Bou-Akl, my mentor and friend.
In addition, I would like to thank the tissue engineering and biomaterials research
group members for their help in the lab and Wayne State University for providing me
iii

with the sufficient fund to complete my graduate studies, allowing me the opportunity to
expand my knowledge and ability.
Finally, I would like to thank all of my friends who have become brothers over the
years specially my best three friends Suhib Rawshdeh, Mahmoud Najeh and Dr.
Dawood Yusef. I could not list all of my wonderful friends but you all know who you are
and you know you are all in my heart.

iv

TABLE OF CONTENTS
Dedication_________________________________________________________

ii

Acknowledgements_________________________________________________

iii

List of Figures______________________________________________________

xi

List of Tables______________________________________________________

xv

CHAPTER ONE: INTRODUCTION_____________________________________

1

CHAPTER TWO: CHITOSAN AND GLYCOSAMINOGLYCANS IN TISSUE
ENGINEERING APPLICATIONS_________________________________

4

2.1 Chitosan__________________________________________________

4

2.2 Glycosaminoglycans (GAGs)__________________________________

5

CHAPTER THREE: HEART VALVE DISEASES AND TISSUE ENGINEERED
HEART VALVES______________________________________________

7

3.1 Significance of Heart Valve Diseases in Pediatrics_________________

7

3.2 Current Treatments of Defective Aortic Heart Valve________________

9

3.2.1 Mechanical Valves___________________________________

9

3.2.2 Biological Valves____________________________________

9

3.3 Tissue Engineered Heart Valve Approach________________________

10

3.4 Parameters Affecting the Tissue Engineered Heart Valve Function____

11

3.4.1 Scaffold Materials___________________________________

11

3.4.2 Static and Dynamic Culturing of Scaffolds_________________

15

CHAPTER FOUR: ADVANCES IN BONE MARROW-DERIVED MESENCHYMAL
STEM CELLS FOR CARDIOVASCULAR TISSUE ENGINEERING_______

20

4.1 Isolation of Mesenchymal Stem Cells (MSCs) From Bone Marrow_____

20

v

4.2 Bone Marrow MSCs in Tissue-Engineered Heart Valves Applications__

20

4.3 Effect of Mechanical stimulations on Bone Marrow-Derived MSCs
Differentiation and Proliferations_______________________________

21

4.4 Effect of Scaffold Matrix Components on Bone Marrow-Derived MSCs
differentiation and proliferations________________________________

22

CHAPTER FIVE: REINFORCING CHITOSAN-BASED HEART VALVE
SCAFFOLD USING CHITOSAN FIBERS___________________________

24

5.1 Introduction_______________________________________________

24

5.2 Experimental Work_________________________________________

26

5.2.1 Materials and Methods________________________________

26

5.2.2 Formation of Chitosan Fibers Using Gel Extrusion Technique_

27

5.2.3 Formation of Chitosan-Based Heart Valve Scaffold_________

28

5.2.4 Formation of Fiber-Reinforced chitosan-Based Disc Scaffold__

29

5.2.5 Formation of Fiber-Reinforced Chitosan-Based Heart Valve
Scaffold___________________________________________

30

5.2.6 Covalent Immobilization of Heparin onto Chitosan Fibers and
Formation of Reinforced Scaffolds with chitosan-Heparin
Fibers____________________________________________

30

5.2.7 Mechanical Testing of Fibers and Fiber-Reinforced Scaffolds_

31

5.2.8 Statistical Analysis___________________________________

31

5.3 Results___________________________________________________

31

5.3.1 Porosity and Mechanical Properties of Heart Valve Scaffolds
and Chitosan Fibers_________________________________

vi

31

5.3.2 Effect of Fiber Length and Fiber/Scaffold Mass Ratio on
Scaffold Mechanical Properties_________________________

33

5.3.3 Effect of Fiber Reinforcement on Chitosan-Based Heart Valve
Scaffolds___________________________________________

37

5.3.4 Partial Dissolution of Chitosan Fibers within Chitosan Scaffold_

39

5.3.5 Effect of Heparin Immobilization on Chitosan Fibers
Mechanical Properties________________________________

40

5.3.6 Effects of Fiber Crosslinking and fiber mechanical properties
on Scaffold Mechanical Properties_______________________

43

5.4 Discussion _______________________________________________

45

5.5 Conclusions and Future Work ________________________________

50

CHAPTER SIX: IMPROVING CHITOSAN FIBER MECHANICAL PROPERTIES
THROUGH PHYSICAL AND CHEMICAL TREATMENTS______________

51

6.1 Introduction_______________________________________________

51

6.2 Experimental Work_________________________________________

53

6.2.1 Materials and Methods________________________________

53

6.2.2 Fabrication of Chitosan Fibers Using Polymer Fiber Extrusion
Technique_________________________________________

53

6.2.3 Measurement of Fiber Diameters_______________________

54

6.2.4 X-Ray Diffraction (XRD) Analysis of Fiber Microstructure_____

54

6.2.5 Evaluating the Mechanical Properties of Chitosan Fibers_____

55

6.2.6 Statistical Analysis___________________________________

55

6.3 Results___________________________________________________

55

vii

6.3.1 Effect of Acetic Acid Concentration on Chitosan Fibers
Mechanical Properties________________________________

55

6.3.2 Effect of Coagulation Bath pH of Ammonia Solution on
Chitosan Fibers Mechanical Properties___________________

58

6.3.3 Effect of Drying Temperature on Chitosan Fibers Mechanical
Properties_________________________________________

62

6.3.4 Effect of Combined Parameters on the Mechanical Properties
of Chitosan________________________________________

66

6.4 Discussion________________________________________________

69

6.5 Conclusions and Future Work_________________________________

71

CHAPTER SEVEN: ISOLATION, CHARACTERIZATION AND PROLIFERATION
OF OVINE BONE MARROW- DERIVED MESENCHYMAL STEM CELLS:
POTENTIAL SOURCE FOR CARDIOVASCULAR TISSUE ENGINEERING

73

7.1 Introduction_______________________________________________

73

7.1.1 Bone Marrow-Derived Mesenchymal Stem Cells (MSC)_

73

7.1.2 Characterization of Bone Marrow-Derived Mesenchymal Stem
Cells_____________________________________________

74

7.1.3 Bone Marrow MSCs in Tissue-Engineered Heart Valves
Applications________________________________________
7.2 Experimental Work_________________________________________
7.2.1 Isolation of Ovine Bone Marrow Mesenchymal Stem Cells____

74
75
75

7.2.2 Cryopreservation of Sheep Bone Marrow Mesenchymal Stem
Cells_____________________________________________

viii

76

7.2.3 Characterization of Bone Marrow-Derived Mesenchymal Stem
Cells (MSCs)__________________________________

76

7.2.4 MSCs Differentiation into Smooth Muscle Cells (SMC)_______

78

7.2.5 Effect of Serum Concentration on MSCs Proliferation and
Attachment_____________________________________________

79

7.2.6 Effect of Immobilized GAGS on MSCs Proliferation and
Attachment_____________________________________________

80

7.3 Results___________________________________________________

81

7.3.1 Isolation of Ovine Bone Marrow-Derived MSCs____________

81

7.3.2 Characterization of MSCs_____________________________

82

7.3.4 Differentiation of MSCs into Smooth Muscle Cells (SMC)_____

87

7.3.5 Effect of Serum Concentration on MSCs Proliferation and
Attachment_________________________________________

91

7.3.6 MSCs Proliferation GAG-Chitosan Membranes_____________

93

7.4 Discussion________________________________________________

96

7.5 Conclusions and Future Work_________________________________

100

CHAPTER EIGHT: EFFECT OF STIFFNESS OF MECHANICALLY IMPROVED
CHITOSAN FIBERS ON BONE MARROW- DERIVED MESENCHYMAL
STEM CELLS ATTACHMENT, VIABILITY AND PROLIFERATION_______

101

8.1 Introduction_______________________________________________

101

8.2 Experimental Work_________________________________________

102

8.2.1 Fabrication of Mechanically Improved Chitosan Fibers_______

102

8.2.2 MSC Culturing and Seeding___________________________

103

ix

8.2.3 MSC Attachment and Viability on Chitosan Fibers with
Different Stiffness___________________________________

103

8.2.4 MSCs Cytoskeleton Organization on Mechanically Improved
Chitosan Fibers_____________________________________

104

8.3 Results___________________________________________________ 105
8.3.1 MSCs Viability and Proliferation on Mechanically Improved
Chitosan Fibers_____________________________________

105

8.3.2 Cytoskeleton Organization in MSCs Cultured on Mechanically
Improved Chitosan Fibers_____________________________

108

8.4 Discussion________________________________________________

110

8.5 Conclusions and Future Work_________________________________

111

References________________________________________________________

112

Abstract__________________________________________________________

129

Autobiographical Statement___________________________________________

131

x

LIST OF FIGURES
Figure 1: Chemical structure of chitosan repeating unit. ________________________ 4
Figure 2: Repeating unit structure of GAGs. _________________________________ 6
Figure 3: Formation of chitosan fibers using gel extrusion technique (left) and Phase
contrast image of hydrogel chitosan fibers with average diameter of ~325µm.
Scale bar is 250 µm. Average diameter was calculated from 40
measurements. ______________________________________________ 28
Figure 4: (A) Unigraphics® image of trileaflet heart valve mold, (B) Ventricular view of
porous chitosan trileaflet heart valve scaffold showing the leaflet (L) and the
cylinder (C) and (C) Aortic view of trileaflet heart valve scaffold showing the
sinus (S) ____________________________________________________ 29
Figure 5: Stress-strain curve of reinforced scaffold at 0.4 fiber/scaffold mass ratio and
unmodified chitosan based scaffold. Reinforced scaffold had a higher strength
and strain values compared to unmodified scaffolds.__________________ 34
Figure 6: Effect of fiber/scaffold mass ratio on scaffold (A) Strength and (B) Stiffness.
(n=7), all values were statistically different from unmodified scaffold. _____ 35
Figure 7: Effect of fibers length on chitosan (A) strength and (B) stiffness. * indicate a
statistical difference (p<0.05). (n=7) _______________________________ 36
Figure 8: Reinforced heart valve scaffold with 2mm fibers length at 1.0 fiber/scaffold
mass ratio showing (A) Strength, (B) Maximum Strain and (C) Modulus of
elasticity. Values were statistically different at each location between the two
conditions (p<0.05). ___________________________________________ 39
Figure 9: Reinforced scaffolds with chitosan fibers. (Left) phase contrast image of
transverse section of scaffold showing the embedded chitosan scaffold were
present within the matrix, scale bar 250µm and (Right) transverse section
SEM image shows porous chitosan scaffold with fibers embedded, scale bar
is 100 microns_______________________________________________ 40
Figure 10: Effect of crosslinking of chitosan fibers with heparin on fibers (A) diameters,
(B) strength, (C) elasticity and (D) stiffness. (n=10) __________________ 43
Figure 11: Effects of chitosan fiber and modified heparin fiber mechanical properties on
scaffold (A) tensile strength and (B) modulus of elasticity. Error bars indicate
standard deviation from 7 samples. Values at each mass ratio for the two
xi

conditions were statistically different except for tensile strength at a ratio of
0.2. _______________________________________________________ 44
Figure 12: Effect of acetic acid (AA) concentration on chitosan fibers (A) diameters, (B)
strength, (C) elasticity and (D) stiffness. ___________________________ 58
Figure 13: Effect of coagulation bath of ammonia solution, (A) chitosan fibers diameters
and (B) XRD spectra of chitosan fibers extruded in 10 or 25 wt% ammonia
solutions. (* p<0.05) __________________________________________ 60
Figure 14: Effect of coagulation bath ammonia solution on chitosan fibers mechanical
properties, (A) fiber strength, (B) fiber elasticity and (C) fiber stiffness.___ 62
Figure 15: Effect of drying temperature on chitosan fiber diameters ______________ 63
Figure 16: XRD spectra of chitosan fibers annealed at different temperature (A) and
height ratio of crystalline to amorphous peaks (B) ___________________ 64
Figure 17: Effect of annealing temperature on (A) chitosan fibers strength, (B) fibers
elasticity and (C) fibers stiffness. _______________________________ 66
Figure 18: Representative Stress-Strain curve of different chitosan fibers formed with
combined parameters ________________________________________ 67
Figure 19: Effect of combing parameters on (A) fiber strength, (B) fiber elasticity and (C)
fiber stiffness________________________________________________ 69
Figure 20: Cell attachment and morphology of MSCs at passage 0 during isolation,
Objective is 10X_____________________________________________ 81
Figure 21: Subculturing of MSCs up to passage 4, objective is 10X ______________ 82
Figure 22: MSCs differentiation into adipocytes. Formation of oil vacuoles indicating
MSCs differentiation into adipocytes at Day 20, Objective 20X _________ 83
Figure 23: Morphological changes in MSCs during their differentiation into osteocytes,
Objective 20X ______________________________________________ 84
Figure 24: Von Kossa and safranin-O staining at higher magnification, upper panel, and
the whole culture plate, lower panel _____________________________ 85

xii

Figure 25: Morphological changes of MSCs during their differentiation into
Chondrocytes, Objective 4X _________________________________ 86
Figure 26: H&E, Safranin-O and Masson’s Trichrome staining confirm the differentiation
of MSCs into chondrocytes _____________________________________ 87
Figure 27: Morphological changes of MSCs during differentiation into SMCs, Objective
10X _______________________________________________________ 88
Figure 28: α-SMActin staining confirms that both MSCs cultured in growth medium or
differentiation medium differentiated into SMC, Objective 20X __________ 89
Figure 29: Amount of Actin production in MSC cultured in growth medium or
differentiation medium _______________________________________ 90
Figure 30: α-SMActin staining of MSC of Passage 0 cultured in DMEM culture medium
without FBS for 1 day, Objective 20X _____________________________ 90
Figure 31: Growth rate of MSC cultured for 5 days in growth medium or differentiation
medium ____________________________________________________ 91
Figure 32: Effect of serum concentration in culture medium on MSCs attachment and
spreading, Objective 10X _____________________________________ 92
Figure 33: Effect of Serum concentration on MSCs proliferation for 5 days culture. __ 93
Figure 34: Cell morphology of MSC cultured on different immobilized GAGs, HS
(Heparan Sulfate), Hep (Heparin Sodium), C4S (Chondroitin-4-Sulfate), HA
(hyaluronic Acid), Chit (Chitosan) and TCP (Tissue Culture Plate).
Objective is 10X. ___________________________________________ 95
Figure 35: Effect of different immobilized GAGs on MSC proliferation for 8 days in static
culture. ____________________________________________________ 95
Figure 36: Stiffness for mechanically improved chitosan fiber __________________ 106
Figure 37: Alamar Blue results of MSC proliferation for 6 days on different fibers with
different stiffness values. _____________________________________ 106
Figure 38: Live/ Dead assay showing MSC attachment and viability on day 3 and 5 of
culture for chitosan fibers with different stiffness values, red-dead cells and
green-live cells _____________________________________________ 107
xiii

Figure 39: Cytoskeleton organization in MSCs on day 9 of culture when cultured on (A)
Fibers dried at RT, (B) fibers dried at RT and Immobilized with Heparin, (C)
Fibers annealed at 195 °C, arrow points to fluorescent chitosan fiber and
(D) MSCs cultured on Tissue culture plate, red: f-actin, blue: nucleus,
Objective 20X. _____________________________________________ 109

xiv

LIST OF TABLES
Table 1: Pore size of heart valve scaffold at different locations __________________ 32
Table 2: Mechanical properties of chitosan fibers and chitosan based scaffolds _____ 32
Table 3: Mechanical properties of chitosan based heart valve scaffold compared to
human pulmonary and aortic valves _______________________________ 33

xv

1

CHAPTER ONE
INTRODUCTION
Current mechanical and biological replacements lack the ability to grow and
remodel with the patient, a limitation that hinders their use in pediatrics patients to
replace the defective aortic or pulmonary valves. Tissue engineered heart valve is a
promising approach to address current problems associated with mechanical and
biological valves and provide a suitable valve replacement to pediatrics patients.
However, tissue engineered heart valves scaffolds made of chitosan , collagen or fibrin
still lack the mechanical integrity and the structural maturity to withstand the
hemodynamic environment in the heart. Additionally, cells type and source are still
among the major issues that greatly affect the cell proliferation and the interaction with
the biomaterial.
Chitosan have been used extensively for many tissue engineering applications.
However, like many other hydrogel polymers, chitosan has many attractive biological
and biocompatibility properties but modest mechanical properties which limit its use in
load-bearing tissue engineering applications.
MSCs isolated from bone marrow are an attractive promising source in the field
of tissue engineering and regenerative medicine. Their use in new cell-based
therapeutic strategies such as mesenchyme-derived tissue repair showed a great hope
to expand their use so far.
The main focus of this research study is to improve the mechanical properties of
chitosan-based heart valve scaffold and to utilize bone marrow-derived mesenchymal
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stem cells (MSCs) for cardiovascular tissue engineering applications. The driving
hypothesis for this research study is that improving the mechanical properties of a
chitosan-based heart valve scaffold to comparable heart valve properties will
improve the bone marrow–derived mesenchymal stem proliferation and direct
their differentiation into heart valve cells.
The specific aims of this study are:
(1)

To evaluate the mechanical properties of chitosan scaffolds and chitosan fibers
and then to evaluate the effectiveness of chitosan fibers reinforcement as a
method for enhancing the mechanical properties of chitosan-based heart valve
scaffolds. The working hypothesis for this aim is that embedding chitosan
fibers within chitosan-based scaffold will improve it mechanical properties.

(2)

To evaluate the effect of various physical and chemical modifications on chitosan
fibers to further improve their mechanical properties and test modified fiber
biocompatibility for tissue engineering applications. The working hypothesis for
this aim is that improving the mechanical properties through physical and
chemical modifications will further improve the mechanical properties of
chitosan-based scaffolds.

(3)

To isolate, characterize and utilize ovine bone marrow-derived mesenchymal
stem cells for cardiovascular tissue engineering applications.

(4)

To evaluate the effect of different immobilized GAGs on MSCs morphology,
attachment, spreading and proliferation. The working hypothesis for this aim is
that immobilized GAGs on chitosan substrates will modulate growth factors
and bind matrix proteins to improve MSCs attachment and proliferation.
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(5)

To evaluate the effect of chitosan fibers stiffness on MSCs attachment, spreading
and proliferation. The working hypothesis for this aim is that improving the
matrix

stiffness

will

improve

MSCs

differentiation into heart valve-like cells.

proliferation

and

direct

their
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CHAPTER TWO
CHITOSAN AND GLYCOSAMINOGLYCANS IN TISSUE ENGINEERING
APPLICATIONS
2.1

Chitosan
Chitosan is a semicrystalline polysaccharide that is formed by repeating units of

N-acetyl-D-glucosamine and D-glucosamine (Madihally and Matthew, 1999). The
degree of crystallinity is highly depended on the degree of deacetylation, while the rate
of degradation is dependent on the degree of deacetylation. Chitosan is insoluble in
most organic solvents in addition to water, however, it is soluble in dilute acid solutions
(pH<5). Its Molecular weight ranges between 100 kDa and 1000 kDa.
Chitosan has been shown to be useful biomaterial in many tissue engineering
applications such as a wound dressing material (Kratz et al., 1997) and drug delivery
vehicle (Aiedeh et al., 1997). It has many attractive biodegradable, biocompatible, nonantigenic, non-toxic and bio-functional properties which expanded its use in different
tissue engineering applications (Madihally and Matthew, 1999; VandeVord et al., 2002).
Figure 1 shows the chemical structure of a repeating unit in a chitosan molecule.

Figure 1: Chemical structure of chitosan repeating unit.
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2.2

Glycosaminoglycans (GAGs)
Glycosaminoglycans (GAGs) are highly sulfated heteropolysaccharide, which

have acidic sulfate and/or carboxyl groups. GAGs are covalently bound to core proteins
forming macromolecules called proteoglycans (Lindahl and Hook, 1978). They are
found on the cell surface or in the extracellular matrices. GAGs are negatively charged
macromolecules that can be immobilized on different surfaces including chitosan
substrates (Chupa et al., 2000). Proteoglycans plays a key role as tissue organizers,
influence cell growth and the maturation of specialized tissues and modulate growthfactor activities (Madihally et al., 1999; Matthews et al., 2000; Cho et al., 2008).
The six major types of GAGs according to their structure of repeating
disaccharide units are: hyaluronic acid (HA), dermatan sulfate (DS), chondroitin sulfate
(CS), heparin sodium (Hep), heparan sulfate (HS) and Keratan sulfate (KS). All GAGs
have a sulfate group and covalently attached to proteins as protoglycans except HA.
Heparin is the most highly sulfated GAG and possesses the highest molecular charge
density.

Hyaluronic Acid (HA)

Dermatan Sulfate (DS)
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Chondroitin 4- and 6-sulfates (C-4-S Heparin and Heparan sulfates(HS)
and C-6-S)

Keratan Sulfates(KS)
Figure 2: Repeating unit structure of GAGs.
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CHAPTER THREE
HEART VALVE DISEASES AND TISSUE ENGINEERED HEART VALVES
3.1

Significance of Heart Valve Diseases in Pediatrics
Congenital heart defects are the leading cause of mortality in pediatrics around

the globe as they are the most common type of birth defects. 8 of every 1,000 newborns
are affected by heart defects. In the United States alone, more than 35,000 babies are
born with one or more congenital heart defects ranging from mild to severe defects.
7,000 babies are born with severe heart defects in the aortic or pulmonary valve
(Flanagan and Pandit, 2003; Zimmermann and Eschenhagen, 2003; Neuenschwander
and Hoerstrup, 2004; Sarkar et al., 2007; Akhtar and Ahmed, 2008; Filova et al., 2009).
Congenital heart defects include: (1) atrial septal defects where a hole is present
in septum between the two atria allowing the mixing of the oxygenated and the
deoxygenated blood between the two sides of the heart, (2) aortic stenosis which refers
to an obstruction to blood flow between the left ventricle and the aorta. The causes of
this obstruction can result from a muscular obstruction below the aortic valve,
obstruction at the aortic valve itself or an immediate narrowing above the aortic valve.
However, the most common aortic stenosis is the obstruction at the valve itself termed
as aortic valvar stenosis.
Bicuspid aortic valve (BAV) is the most common abnormality that occurs to the
aortic valve when two leaflets are existed instead of three leaflets. The leaflets in BAV
are often less pliable and more thickened and the lines of separation between the
leaflets (i.e. commissures) are fused together to compensate the loss of the third leaflet.

8
The aortic valve in this case would not open and close freely. To compensate the
malfunction of the aortic valve, the left ventricle should provide extra force to eject the
blood into the aorta, which often results in ventricular hypotrophy as a result of
ventricular muscle thickening. In severe aortic valve obstruction where ventricular
muscle is unable to compensate adequately, patients may develop cardiac failure,
which is a common case in newborn infants.
Newborn babies with severe aortic stenosis usually develop cardiac failure in the
first few days of life which necessitates an instant treatment by either balloon dilation of
the valve or surgery. Balloon dilation valvuloplasty is usually completed at the time of
catheterization through the umbilical artery for newborns (Filova et al., 2009). Surgical
valvotomy or open heart procedure is used when simple balloon dilation is not sufficient.
This procedure involves the opening of the valve along the lines of commissures.
Complete surgical aortic valve replacement will be necessary when aortic valve is
obstructed by sever calcium deposits in the leaflets or when the valve ring is small and
underdeveloped. Ross procedure for aortic valve replacement is commonly used to
replace the defective aortic valve with the patient own pulmonary valve where the
pulmonary valve will be replaced with a homograft valve (i.e. human donor valve). The
main advantage of this procedure is that the replaced aortic valve continues to grow
with the child. However, the availability of a donor pulmonary valve and immune system
rejection are some of the major hindrances for this approach.
The Implantation of a mechanical or biological valve in the aortic valve place is
traditionally used when no donor valves are available for immediate implantation. In
2003, the number of patients who required heart valve transplantation was 295,000
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patients (Filova et al., 2009). This number is expected to reach 850,000 patients by
2050 (Yacoub and Takkenberg, 2005). Current heart valve replacements use
mechanical valves in 60% of the replacement cases while biological valves are used in
remaining 40% of replacement cases (Mol and Hoerstrup, 2004).
3.2

Current Treatments of Defective Aortic Heart Valve

3.2.1 Mechanical Valves
Mechanical valve is a non physiological design that resides in close contact with
the blood resulted in causing turbulent blood flow. The use of these valves requires a
lifetime of anticoagulation therapy. Due to the modest lifespan of these valves, that is 15
years, they are mainly used in adults patients.
Mechanical valves lack the ability to grow with the patient which limits their use in
pediatric patients. Hemolysis and platelet activations are some of the main side effects
that result from the turbulent blood flow. Apart from this, problems in fertile females may
occur due to embryo-toxicity of warfarin and other substances used in anticoagulation
therapies (Neuenschwander and Hoerstrup, 2004).
3.2.2 Biological Valves
Biological valves (xenografts and autografts) have been used in parallel with the
mechanical valves over the past decades to treat the defective valves. These valves do
not require lifetime anticoagulation; however, they have limited durability due to
calcification which shortens their life span to 10 years.
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Heterografts valves are decellularized valves which are usually obtained from
different species, yet they lack the ability to remodel or grow with patient. These valves
have also been shown to have inadequate mechanical properties and immunological
concerns (Filova et al., 2009). With all the aforementioned problems, biological valves
are not a practical alternative to replace heart valves in newborn patients.
3.3

Tissue Engineered Heart Valve Approach
Replacing the defective heart valve in infants is quite different and far more

challenging problem as oppose to adults patients. The replaced valve should be viable,
able to grow, remodel and perform its function adequately for a longer period of time.
The ultimate goal of all tissue engineered heart valves (TEHV) is to seed cells onto a
biodegradable scaffold and transplant it instead of the defective valve. The scaffold is
expected to provide adequate amount of mechanical strength to stimulate the growth of
new tissue. This scaffold then becomes part of patient’s tissue and restores the natural
function of the valve after certain amount of time.
Despite the significant research efforts that have been conducted over the past
decade to produce optimal TEHV (Shinoka et al., 1995; Niklason and Langer, 1997;
Steinhoff et al., 2000; Flanagan and Pandit, 2003; Zimmermann and Eschenhagen,
2003; Neuenschwander and Hoerstrup, 2004; Sarkar et al., 2007), some of these trials
using either synthetic or natural scaffolds were limited by the structural immaturity and
the inadequate mechanical properties (Hoerstrup et al., 2000). Researchers have
investigated different approaches to improve the mechanical properties of synthetic
scaffolds

mainly.

The

majority

of

these

approaches

focused

on

materials
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characterizations of scaffolds and/or mechanical conditioning of scaffolds via static and
dynamic culturing (Flanagan and Pandit, 2003; Engelmayr et al., 2005).
3.4

Parameters Affecting the Tissue Engineered Heart Valve Function
Despite the wide range of investigated scaffolds as extracellular matrix (ECM)

templates for TEHV, current scaffolds still lack the mechanical integrity and the
structural maturity to withstand the hemodynamic environment in the heart (Hoerstrup et
al., 2000; Sodian et al., 2000; Sodian et al., 2000; Sodian et al., 2000; Sodian et al.,
2006). The following sections will focus on the studied parameters that greatly affect the
mechanical properties of heart valves scaffolds.
3.4.1 Scaffold Materials
3.4.1.1 Decellularized Heart Valves Scaffolds
Using detergents and enzymes, Wilson et al (Wilson et al., 1995) developed a
protocol in 1995 to decellularize canine heart valves. They removed most of cell
membranes, lipids, nucleic acids and the soluble matrix molecules. The amount of
collagen and elastin remained in the ECM was suitable to recellularize the valve. Nearly
one month after implantation, histology analysis showed no inflammatory response,
fractional valvular interstitial cells (VIC) penetration at the valve base and partial
endothelial cells formation. However, this study did not provide any long term
calcification studies or mechanical properties evaluation.
Bader and colleagues in 1998 (Bader et al., 1998) decellularized porcine aortic
valve and reseeded it with human endothelial cells and implanted it again. Their results
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demonstrated that there was no evidence of cell throughout the thickness of the leaflet.
Collagen formation was comparable to native valve with wavelike structure, however,
the presence of huge interfibrillar space was significant, which could explain the low
mechanical properties obtained.
In 2000, Steinhoff et al (Steinhoff et al., 2000) acellularized sheep heart valve
and then reseeded it with myofibroblasts for six days and then with endothelial cells for
two days. Acellularized and reseeded valves were then implanted in a sheep model. For
three months, the reseeded valves and the acellularized valves showed normal
function. However, after that, the acellularized valves showed partial degradation and
no new tissue formation, while the reseeded valves showed confluent endothelial
surface, myofibroblasts, and collagen I. Histological analysis showed inflammatory
response leaded to calcification. Additionally, leaflet thickness increased which caused
a valve stenosis limiting the free opening and closing of the valve.
SynerGraft™ valve is a commercial decellularised valve available through
CryoLife Incorporation in the US. human studies showed early failure of the valve within
the first year of implantation due to structural failure and/or rapid deterioration (Simon et
al., 2003).
3.4.1.2 Natural Polymers Heart Valve Scaffolds
Among the most two investigated natural scaffolds for TEHV are fibrin gel and
collagen (Ye et al., 2000; Jockenhoevel et al., 2001; Grassl et al., 2002; Neidert et al.,
2002; Tschoeke et al., 2009; Koch et al., 2010). Fibrin gel is a biodegradable polymer
that can be produced easily and quickly from blood. Fibrin gel has many attractive
properties which make it a good candidate for heart valve scaffolds. Fabrication of fibrin
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gel scaffold from patient’s blood is an easy process and eliminates any risk of
immunological rejection. The degradation rate of this scaffold can be easily controlled.
Also homogenous distribution of cells can be achieved when manufacturing scaffold
(cell/fibrin tissue structure) (Jockenhoevel et al., 2001; Flanagan and Pandit, 2003;
Zhou et al., 2006; Sarkar et al., 2007). However, when fibrin gel structure was used to
fabricate trileaflet scaffold, the mechanical properties of the structure were not adequate
for implantation (Ye et al., 2000).
Collagen was investigated to fabricate heart valve scaffolds (Chevallay and
Herbage, 2000; Rothenburger et al., 2001; Taylor et al., 2002); however collagen
scaffolds were shown to be very weak and require Dacron mesh to strengthen them.
Additionally, collagen scaffolds have been shown to perform poorly over contraction
which reduces the matrix permeability (Lewus and Nauman, 2005; Sarkar et al., 2007).
3.4.1.3 Synthetic Polymers Heart Valve Scaffolds
Polyglycolic acid (PGA), polylactic acid (PLA), and their copolymers (PGLA) are
among the most synthetic polymers that have been investigated extensively in
fabricating TEHV (Flanagan and Pandit, 2003; Sarkar et al., 2007). The first use of PGA
was in 1995 by Shinoka et al (Shinoka et al., 1995; Shinoka et al., 1996). They
fabricated a single leaflet made of PGLA woven mesh sandwiched between two
nonwoven PGA meshes. The leaflet was seeded with myofibroblasts and then with
endothelial cells; thereafter, the leaflet was implanted in an ovine model at the
pulmonary valve position. Their results after six weeks demonstrated cellular
distribution, new tissue formation, elastin and collagen production and mechanical
properties similar to the native leaflet. However, infections and inflammatory responses
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in animals were observed. The histological analysis showed that the leaflet was
immalleable to function due to the high initial stiffness and thickness of composite
PLA/PGA polymers.
Sodian et al in 2000 (Sodian et al., 2000) choose polyhydroxyoctanoate (PHO) to
be part of composite valve scaffold. Four different materials were used to fabricate the
valve scaffold: nonporous film of PHO was used in the wall sandwiched between two
layers of nonwoven PGA, the leaflet made out of single layer of porous PHO,
polydioxanone sutures used to suture the leaflet to the wall. Histological analysis
showed organized tissue formation and significant amount of collagen. However,
formation of elastin was absent. After 24 weeks, degradation analysis showed that the
scaffold was still in the conduit and did not degrade, which suggests longer degradation
time than PGA. This might lead to tissue reaction in the future. Another limitation of this
study is that it was implanted at low pressure profile.
Another study by Sodian et al in 2000 (Sodian et al., 2000), incorporated the use
of PHO with PGA to fabricate trileaflet scaffold. Scaffold was seeded with
myofibroblasts and endothelial cells and implanted in ovine model for 17 weeks. All
valves performed properly upon opening and closing. Although smooth blood flow was
observed and collagen and GAGs were deposited, elastin was absent. Additionally,
there was no formation of endothelial layer which could limit the durability of this
scaffold.
Poly-4-hydroxybutyrate (P4HB) was evaluated as a composite scaffold with PGA
by Mol and colleagues in 2006 (Mol et al., 2006; Schmidt et al., 2006). Trileaflet scaffold
was fabricated using the composite material and seeded with myofibroblasts and
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endothelial cells, and then cultured in a bioreactor for 14 days, and then implanted in
ovine model for 20 weeks. The scaffolds showed uniformly and organized formation of
new tissue characterized by the formation of collagen and a loose layer of elastin and
GAGs. However the valves showed mild to moderate stenosis at 20 weeks in vivo with
partial formation of endothelial cell at the leaflet surface.
3.4.2 Static and Dynamic Culturing of Scaffolds
TEHV bioreactors are used in which the in vivo biomechanical and biochemical
conditions are mimicked in vitro to produce a functional tissue development (Barron et
al., 2003; Freed et al., 2006). These conditions include: the opening and the closing
behavior of the valve at 1Hz frequency, flow rate, pressure and shear stress.
Barron et al (Barron et al., 2003) suggested that culturing tissue-engineered
heart valves in an initial low shear stress with exposure the developing tissue to
physical stimulus is advantageous for initial tissue development. The design and the
use of bioreactors in tissue-engineered heart valves greatly vary depending on the
application and the desired goals. Heart valve bioreactors are used in vitro before
implantation to improve cell seeding efficiency, cell proliferation and penetration within
the scaffold, the production of ECM components and the mechanical properties of the
scaffold to withstand the real hemodynamic environment in vivo (Unsworth and Lelkes,
1998; Hoerstrup et al., 2000; Gulbins et al., 2005; Mol et al., 2006; Sodian et al., 2006).
The effect of time and flow rate of tissue-engineered heart valves constructs that
are cultured in a bioreactor is still not fully understood. To better understand this major
effect, Mol and colleagues (Mol et al., 2006) cultured polyglycolic acid (PGA) heart
valves scaffolds coated with Poly-4hydroxybutyrate (P4HB) in two different diastolic
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pulse duplicator (DPD) bioreactors for 4 weeks. The first set of scaffolds was cultured in
dynamic bioreactor by varying the pressure from 5-30 mmHg. The second set was
cultured in a static bioreactor under constant flow rate (4ml/min). To mimic the opening
and the closing of the aortic heart valve, they applied a dynamic pressure gradient over
the valve (1Hz). After four weeks, their results showed that the valve constructs that
were cultured in dynamic bioreactor have significantly higher GAGs production and
improved mechanical properties in the radial direction only than the static bioreactor or
control cultured flasks, whereas the collagen production increased significantly with the
use of dynamic bioreactor to be comparable to the native valve, but was lower than the
static bioreactor. The effect of the culturing time was also one of the major goals for this
study. They realized that the collagen and GAGs production increased over the time up
to four weeks and were stable thereafter. The effect of culturing time significantly
improved the biomechanical properties to be comparable to the native aortic valve in the
radial direction only again in the radial direction but not in the circumferential direction.
The opening of the valve was optimal, while the closing of the valve was suboptimal
where the valve did not form a tight sealing. The absence of elastin formation proved by
histology analysis of scaffolds after four weeks of culturing in a dynamic bioreactor was
a major cause of tissue creep. So, even though this study is considered as one of the
most comprehensive studies conducted recently to fully understand the effect of the
bioreactor on many tissue properties, still more comprehensive studies are needed in
this field to optimize the most advantageous culture time and pressure for new tissue
formation in vitro before implantation.
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Few studies have been conducted so far to optimize the optimal flow/pressure
profile that helps the formation of neo-tissue. To address the problem of low flow rate
profile, Litchtenberg and colleagues (Lichtenberg et al., 2006) in 2005 seeded
decellularized ovine pulmonary heart valves with endothelial cells under simulated
physiological conditions for two days. The initial flow was 0.1L/min, and then gradually
increased 0.3L/min/day up to 2L/min with a cycle rate of 60beats/min as a way to mimic
the fetal development of the heart valves, with keeping pH, gases levels (CO2 and O2),
glucose, and lactate at constant natural levels. Their results demonstrated that a
monolayer of endothelial cells covered the inner valve surface after seven days for eight
constructs that were cultured in a dynamic bioreactor. The biomechanical properties
revealed comparable values to the native valve tissue in both radial and circumferential
directions. The production of ECM components (collagen, elastin, and GAGs) was
comparable to the native valve. Stable cell-matrix connection was achieved by an initial
low pressure with a gradual increase. This study was the first to demonstrate that a
biological scaffold showed evidence of sufficient stability under high flow rate. This
study also proved the importance of continuous adjustment of the physiological
parameters and the bioreactors design according to the type of scaffolds (synthetic or
biological), and cell type and/or source to improve heart valve results. Despite the fact
that this study was the first study to have analogous results to the native valve tissue in
all aspects, long-term animal studies should convey comparable results to be able to
move this success to clinical human studies in the near future.
In some previous studies, specifically with synthetic scaffolds, it was found that
tissue-engineered heart valves had inadequate mechanical strength or functional
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performance (Hoerstrup et al., 2002; Tang et al., 2005) . A hypothesis has been
proposed by Hoerstrup and colleagues (Hoerstrup et al., 2002) that growing tissue
constructs in a biomimetic bioreactor would produce more mature heart valve constructs
with more favorable performance in vivo. So, to evaluate the effect of bioreactor on
tissue formation of scaffolds conditioned in vitro before implantation, Hoerstrup and his
colleagues (Hoerstrup et al., 2000) grew PGA scaffolds coated with P4HB seeded with
endothelial cells in vitro by culturing them in a diastolic pulse duplicator for 14 days by
varying the pressure-flow rate from 30mmHg (70ml/min) up to 55mmHg (125ml/min),
and then implanted them at the pulmonary valve in six animal models for 20 weeks as
proposed previously in literature for complete remodeling. Their results for scaffolds
before implantation showed synchronous opening and closing of the valves in the
bioreactor under low pressure (35mmHg) and high pressure (>150mmHg). Tissue
analysis after 14 days of culturing in the bioreactor showed dense fibrous tissue near to
the surface of the leaflet, while it was loose near to the central core compared to loose
and poorly organized tissue in the static control. They also demonstrated that the
amount of collagen, GAGs, and DNA were higher than the control at day 14 of culturing
and comparable to the native heart valve values, while the elastin was not detectable in
any leaflets. Suture retention strength was significantly higher when compared to the
static control. In vivo studies at 16 and 20 weeks showed that the leaflet had a loose
spongy layer on the ventricular side (inflow), while a fibrous layer was formed on the
arterial flow (outflow) side. Collagen in the fibrous layer and GAGs in the central core
were detectable at 20 weeks, where elastin was only detectable near the inflow surface
after 6 weeks. Mechanical testing showed a comparable stress-strain behavior and
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values between the tissue-engineered valves and the native one. Despite all of those
promising results, regurgitation was present at 16 and 20 weeks due to the
noncoaptation of valve as a result of scaffold shrinkage during of scaffold degradation.
This issue can be compensated by optimizing the design of the scaffold to initially
increase the coaptive area of the leaflets and by optimizing the ideal time between the
implantation and the degradation of the scaffold. These results are just preliminary
results and should be extended more in terms of the number of implanted valves and
the implantation time.
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CHAPTER FOUR
ADVANCES IN BONE MARROW- DERIVED MESENCHYMAL STEM CELLS FOR
CARDIOVASCULAR TISSUE ENGINEERING
4.1

Isolation of Mesenchymal Stem Cells (MSCs) From Bone Marrow
Human mesenchymal stem cells (hMSCs) were discovered by Friedenstein in

1970’s (Miao et al., 2006). hMSCs are present in adult bone marrow are believed to be
multipotents cells (Pittenger et al., 1999). hMSCs have the ability to replicate as
undifferentiated cells and differentiate to various mesenchymal tissue lineages such as
bone, cartilage, fat, tendon, muscle and marrow stroma (Rebelatto et al., 2008). Upon
isolation and culturing, MSCs displayed a stable phenotype and grew as a monolayer in
vitro. Several studies have shown that MSCs possess the ability to exclusively
differentiate upon induction into adipogenic, osteogenic and chondrogenic lineages
(Pittenger et al., 1999; Sutherland et al., 2005; Rebelatto et al., 2008).
4.2

Bone Marrow MSCs in Tissue-Engineered Heart Valves Applications
MSCs can be easily isolated from the bone marrow in animals and humans.

Possible locations in humans and animals are iliac crest, femur and sternum. MSCs can
be phenotypically converted into endothelial cells (EC) in vitro (Song et al., 2007).
MSCs can also provide a source for fibroblasts/ myofibroblasts and smooth muscle cells
(SMC) (Song et al., 2007; Kurpinski et al., 2010; Song et al., 2010). Recent research
efforts investigated the potential of bone marrow MSCs to differentiate when seeded on
synthetic heart valve scaffolds (Sutherland et al., 2005). MSCs isolated from bone
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marrow were seeded PGA/PLLA nonwoven meshes semilunar heart valve scaffolds
and statically cultured for 4 weeks and then implanted at the pulmonary position into
sheep for 8 months. At the end of the study, MSCs showed the ability to differentiate
into SMC, EC and fibroblasts. The results also showed that histological structure similar
to the native heart valve was obtained.
Another research effort investigated the seeding of MSCs isolated from bone
marrow on PGA/ P4HB composite heart valve scaffolds (Perry et al., 2003). Scaffolds
were cultured for 1 week statically and then transferred to pulse duplicator bioreactor for
2 weeks. The preliminary results showed patchy surface confluency of cells and deep
cellular material. However, the study did not perform immunohistochemistry to
determine the type of the cells covered and penetrated the surface. Biomechanical
testing showed that the leaflets had a comparable stiffness to the native heart valve.
4.3

Effect of Mechanical stimulations on Bone Marrow-Derived MSCs
Differentiation and Proliferations
In addition to the biochemical stimulations that control MSCs proliferation and

differentiation, biomechanical stimulations (i.e. dynamic culturing) are believed to be
important for controlling MSCs behavior. Several studies have shown previously that
culturing heart valves in a dynamic environment has greatly influenced cell proliferation
and ECM deposition (Hoerstrup et al., 2002). However, optimal dynamic conditions are
still unknown and need further investigations.
Recently, a study revealed that cyclic flexure and laminar flow accelerates the
tissue formation of MSCs seeded that are on scaffold (Engelmayr et al., 2006). The
Study aimed to determine the appropriate mechanical stimuli for MSCs cultivation. The
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independent and coupled effects of two main physiological mechanical stimuli that affect
the heart valves function were studied-Cyclic flexure and laminar flow (i.e. shear stress).
MSCs were isolated from sheep bone marrow and seeded onto rectangular strips of
nonwoven 50:50 blend PGA/PLLA and statically cultured for 4 days. After the static
culture, the scaffolds were loaded into flex-stretch-flow bioreactor. 4 groups were
studies; static, cyclic flexure laminar and flex-flow and incubated for 1 and 3 weeks. The
results showed that by 3 weeks, flex-flow group showed a dramatic accelerated tissue
formation compared to all other groups. The new tissue formation was determined by
higher collagen formation and scaffold stiffness.
4.4

Effect of Scaffold Matrix Components on Bone Marrow-Derived MSCs
Differentiation and Proliferation
A recent study showed that scaffold matrix greatly influences the behavior of

seeded MSCs on heart valve leaflets (Iop et al., 2009). Human bone marrow MSCs
were isolated and seeded statically on decellularized porcine and human heart valve
leaflets in culture plates for 30 days. The cells were seeded onto fibrosa or ventricularis
leaflets. The results showed that both human and porcine valves showed no
histopathological features. On the contrary, both valves reconstructed endothelium
lining and fibroblasts, myofibroblasts and SMCs were presents as in the corresponding
valve. Also the results revealed that porcine and human valves behaved differently
where human valve showed more spreading and differentiation indicating that the
matrix-cell source influenced the behavior of the MSCs. Also, with respect to the human
valve, the results showed also that MSC spreading, differentiations, enhanced cell
survivals and colonization were higher in the ventricularis than the fibrosa. This
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suggests that MSC phenotypic conversion is influenced in vitro by the anisotropic
properties of the heart valve.
The signal transduction of the cell-matrix interaction has been shown recently to
influence the differentiation of MSCs into SMCs (Suzuki et al., 2010). MSCs cultured on
dishes that were coated with laminin, collagen IV and fibronectin for 7 days. Also MSCs
were seeded on biodegradable scaffold coated with laminin and implanted into rat
subcutaneous space. Results showed that MSCs numbers increased on collagen
dishes. Dishes coated with laminin showed higher expression of α-smooth muscle actin
and calponin than other culture dishes. In vivo studies showed that fully differentiated
MSCs into SMCs were confirmed by the expression of smooth muscle marker (SM2)
within 2 weeks.
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CHAPTER FIVE
REINFORCING CHITOSAN-BASED HEART VALVE SCAFFOLD USING CHITOSAN
FIBERS
5.1

Introduction
In tissue engineering, scaffolds serve as a biological and mechanical support for

cell growth and functionality. Appropriate selection of cells and scaffold is required to
produce an effective tissue engineered construct. Recent studies have demonstrated a
strong correlation between scaffold strength and/or stiffness and cell behavior (Dikovsky
et al., 2008; Dado and Levenberg, 2009) . It has also been shown that scaffold stiffness
influences the differentiation of mesenchymal stem cells (MSCs) to specialized cell
types (Engler et al., 2004; Engler et al., 2006). However, attaining appropriate
mechanical properties in scaffolds is still a challenge in general, and in heart valve
scaffolds in particular (Hoerstrup et al., 2000).
Natural polymers such as collagen and fibrin have been investigated as potential
scaffolds for cardiovascular tissue engineering due to the high strength they impart
(Ikari et al., 2000; Ye et al., 2000; Lewus and Nauman, 2005; Sarkar et al., 2007).
However, collagen-based scaffold were very weak and required a Dacron mesh to
provide initial strength to prevent rupture at very low pressure of <10 mmHg (Weinberg
and Bell, 1986). With incorporating two Dacron meshes, burst pressure increased up to
180 mmHg but usually failed through the development of pinhole leak. Fibrin gel was
used to fabricate a trileaflet heart valve and seeded with myofibroblasts (Jockenhoevel
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et al., 2001). Despite that the mechanical integrity of fibrin gel model was enough to
withstand the suturing; it was insufficient for direct implantation.
Chitosan is a natural polymer that has low to moderate mechanical properties
that limit its use in load-bearing tissue engineering applications such as heart valves
and large blood vessel constructs. In contrast to natural polymers, synthetic polymers
have more controllable mechanical properties (Flanagan and Pandit, 2003). However,
high initial mechanical properties for some synthetic polymers such as polyglycolic acid
(PGA) have been proved to be immalleable to function as a flexible valve leaflet
structure (Shinoka et al., 1995). This inflexibility in valve structure prevents proper
opening and tight closing of engineered valve leaflets (Shinoka et al., 1995; Shinoka et
al., 1996). Hence, controlling the mechanical properties of scaffolds independent of
changes in scaffold chemistry, degradation rate and biocompatibility is still a significant
challenge.
The reinforcement of weak scaffolds with fibers through natural or synthetic fibers
has been investigated previously (Weinberg and Bell, 1986; Li et al., 2006; Li et al.,
2006). It was shown that increasing the number of Dacron meshes used to reinforce
collagen gel improved the burst strength of the scaffold (Weinberg and Bell, 1986). Li
and colleagues (Li et al., 2006) used chitin fibers to reinforce collagen–based scaffolds
and demonstrated improvement in the mechanical properties of the reinforced scaffold.
Recently, the same group investigated the use of chitin fibers to reinforce poly (L-Lactic
Acid) (PLLA) scaffolds (Li et al., 2009). They showed that reinforced scaffolds had
better cell attachment, proliferation, differentiation and mineralization compared to
unmodified PLLA scaffolds. Wang and colleagues produced a nano-fibrous PLLA

26
scaffold through a thermally-induced phase separation method (Wang et al., 2009). The
scaffold was then reinforced with chitosan fibers dispersed within the solution
ultrasonically. Although, this study utilized chitosan fibers as a reinforcement method,
detailed investigation on the effects of mechanical properties of fibers or fiber
dimensions have not been explored. Moreover, the study has evaluated the
compressive modulus for dry chitosan samples only. A more realistic approach would
be to evaluate the mechanical properties of the scaffold in the wet state since wet
scaffolds are known to behave differently due to the lower mechanical properties
caused by swelling. Moreover, fiber dimensions and mechanical properties should be
studied first to understand their effect on fiber-reinforced scaffold.
This study seeks to fabricate a mechanically viable chitosan-based tissue
engineered heart valve construct. In an attempt to improve the mechanical properties of
the chitosan-based scaffold, the effectiveness of reinforcing the chitosan scaffold with
chitosan fibers was investigated. The main goal of this study is to evaluate the
effectiveness of fiber-reinforced approach to improve the mechanical properties of
chitosan-based scaffolds. The working hypothesis is that embedding chitosan fibers
within a chitosan heart valve scaffold would improve its mechanical properties.
In this study, effects of fiber length, fiber/scaffold mass ratio and heparin modification of
fibers on the mechanical properties of porous chitosan scaffolds were investigated.
5.2

Experimental Work

5.2.1 Materials and Methods
Heparin sodium USP (average molecular weight 10-12 KDa) was purchased
from Celsus Laboratories (Cincinnati, OH). High molecular weight and medium
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molecular weight (HMW& MMW) chitosan from crab shells (MW of 450 KDa and 190310

KDa

respectively,

75-85%

degree

of

deacetylation)

and

1-ethyl-3-(3-

dimethylaminopropyl)-carbodiimide (EDC) were purchased from Sigma-Aldrich (St.
Louis, MO). All other chemicals and solvents were of analytical reagent grade.

5.2.2

Formation of Chitosan Fibers Using Gel Extrusion Technique
Chitosan fibers were formed by gel extrusion technique. Briefly, high molecular

weight (HMW) chitosan was dissolved in 0.2 M acetic acid and stirred for 6 hours to
form a 1.5 wt% solution. Due to hardware limitation, a 26-guage Teflon catheter was
used to extrude the solution. The solution was then extruded through the 26-gauge
(internal diameter 0.45 mm) Teflon catheter directly into 10 wt% ammonia solution using
a syringe pump at a rate of 85 ml/hr as shown in Figure 3. Fibers were left for 15
minutes in the ammonia solution to neutralize. After neutralization, hydrogel chitosan
fibers were then air-dried under tension at room temperature.
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Figure 3: Formation of chitosan fibers using gel extrusion technique (left) and Phase
contrast image of hydrogel chitosan fibers with average diameter of ~325µm. Scale bar
is 250 µm. Average diameter was calculated from 40 measurements.
5.2.3

Formation of Chitosan-Based Heart Valve.
Unigraphics NX computer aided design software (Siemens Aktiengesellschaft,

Munich, Germany) was used to generate a model of a heart valve prosthesis based on
published physiological measurements by Mano Thubrikar and others (Thubrikar, 1990;
Jockenhoevel et al., 2001) . The model consisted of a hollow cylinder containing three
valve leaflets in the closed and open leaflets positions (Figure 4 A). The valve model
was converted to a model of a negative mold and the mold was fabricated in silicone
elastomer using a commercial rapid prototyping service. Porous chitosan heart valve
scaffolds were fabricated by filling the silicone trileaflet mold with 6 ml of 2 wt% medium
molecular weight (MMW) chitosan dissolved in 1 vol% acetic acid. Freezing was
initiated by application of liquid nitrogen to the ventricular side of the mold leaflet surface
for 5 minutes followed by immersion of the entire mold in a dry ice-isopropanol bath for
3 hours. Freezing with liquid nitrogen produces smaller pore size compared to freezing
in dry ice isopropanol. With this freezing approach, aortic side will have bigger pore size
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allowing the cells to be entrapped at the ventricular side which has smaller pore size.
The frozen structure was then lyophilized overnight and the ventricular side of porous
chitosan scaffold is shown in Figure 4 B and the aortic side is shown in Figure 4 C. Pore
sizes were determined by analysis of SEM images of dry scaffolds using Sigma Scan
Pro image analysis software (SPSS Inc., Chicago, IL).

Figure 4: (A) Unigraphics® image of trileaflet heart valve mold, (B) Ventricular view of
porous chitosan trileaflet heart valve scaffold showing the leaflet (L) and the cylinder (C)
and (C) Aortic view of trileaflet heart valve scaffold showing the sinus (S)
5.2.4

Formation of Fiber-Reinforced Chitosan-Based Disc Scaffold
Chitosan disc scaffolds were formed by transferring 9 ml of chitosan solution

into 35 mm Petri dishes, freezing in a dry ice-isopropanol bath at -70°C for 3 hours and
then lyophilizing overnight. Fiber-reinforced disc scaffolds were formed by first
embedding chitosan fibers (2 mm or 10 mm in length) homogenously in the chitosan
solution at four different fiber/scaffold mass ratios (0, 0.2, 0.3 and 0.4 on a dry weight
basis) prior to freezing.
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5.2.5

Formation of Fiber-Reinforced Chitosan-Based Heart Valve Scaffold.
Similarly to fiber-reinforced disc scaffold, fiber-reinforced heart valve scaffolds

were formed by distributing some fibers in the mold. Due to the electrostatic charges,
chitosan fibers were held in place after being distributed within the silicon mold.
Chitosan solution was then added gradually to the mold with distributing more fibers
while filling the mold. Embedded chitosan fibers were of 2 mm length and at a
fiber/scaffold mass ratio of 1.0. As the leaflet is considered the most functional part
within the valve scaffold, 0.4 fiber/scaffold mass ratio were used to reinforce the leaflet
and the remaining fibers were used to reinforce the sinus and the cylinder of the valve.
5.2.6 Covalent Immobilization of Heparin onto Chitosan Fibers and Formation of
Reinforced Scaffolds with Chitosan-Heparin Fibers.
Chitosan fibers were generated using the gel extrusion technique described
above in section 5.2.2.1. After neutralizing in ammonia solution for 15 minutes, chitosan
fibers were immersed overnight in a pre-activated heparin solution. Briefly, heparin at
0.6 chitosan/heparin mass ratio was dissolved in phosphate buffered saline (PBS) and
activated by adding a 10 fold molar excess of EDC (1:1 mass ratio). Chitosan fibers
were immersed in the pre-activated heparin solution and the reaction was allowed to
take place for 24 hours. Heparin-derivatized chitosan fibers were then dried under
tension at room temperature. Heparin-derivatized fibers were characterized by
measuring the fiber diameters before and after hydration in PBS solution for 15 minutes.
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5.2.7

Mechanical Testing of Fibers and Fiber-Reinforced Scaffolds.
After rehydration, mechanical properties of individual fibers were determined in

the wet state using uniaxial tensile testing on a MTS Bionix 100 testing machine, at a
constant strain rate of 1 min-1. After lyophilization, scaffolds were initially neutralized
with 2 wt% ammonia solution for 10 minutes then washed 4 times with PBS.
Rectangular samples (7 x 2 x 15 mm) were cut from disc scaffolds and tested in the wet
state. Mechanical testing was done as for fibers. Maximum stress, breaking strain and
modulus of elasticity at 2% (fibers) and 20% (scaffolds) strain were determined from the
stress-strain plots.
5.2.8

Statistical Analysis.
Statistical comparisons of data were performed using Student’s t-test with a

95% confidence limit. Data are presented as mean ± standard deviation. Differences
with p<0.05 were considered significant.
5.3

Results

5.3.1 Porosity and Mechanical Properties of Heart Valve Scaffolds and Chitosan
Fibers.
Table 1 shows pore sizes of heart valve scaffolds at different locations. Local
freezing conditions yielded different pore sizes at different locations within the scaffold
that were adequate for cell penetration upon seeding. The aortic side had a larger pore
size of 130 µm compared to the ventricular side that had a mean pore size of 54 µm.
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The outer surface of the valve cylinder had a smaller pore size (70 µm) than the inner
surface (115 µm).
Measurements of chitosan fibers after rehydration showed an average diameter
of 320 µm (Figure 3). Mechanical testing demonstrated that chitosan fibers had higher
mechanical properties compared to chitosan-based valve scaffolds as shown in Table 2.
Scaffold tensile strength was 58 kPa and stiffness was 70 kPa. These values are lower
than the values of both human pulmonary and aortic valve strength and stiffness in the
radial and the circumferential directions (Stradins et al., 2004) as shown in Table 3.
Table 1: Pore size of heart valve scaffold at different locations
LeafletLeafletCylinderCylinder-Inner
Aortic
Ventricular
Outer
side
Location
Side
Side
side
(µ
µm)
(µ
µm)
(µ
µm)
(µ
µm)
Mean ± SD

130±73

54±45

115±60

70±39

Median

104

32

101

63

Minimum Value

38

15

37

23

Maximum Value

308

161

352

200

Table 2: Mechanical properties of chitosan fibers and chitosan based scaffolds
Chitosan Fibers
Chitosan Scaffold
Mechanical Aspect
(n=10)
(n=7)
Tensile Strength (kPa)

750±80

58±28

Maximum Strain (%)

20±4

90±30

Modulus of Elasticity (kPa)

3500±780

70±10
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Table 3: Mechanical properties of chitosan based heart valve scaffold compared to
human pulmonary and aortic valves
Chitosan-

Human Pulmonary

Human Aortic

Mechanical

Based Heart

Valve (Radial/

Valve (Radial/

Aspects

Valve Scaffold

Circumferential

Circumferenti

(n=7)

Direction)

al Direction)

Ultimate Stress

320±40 /
58±28

290±60 / 2,780±1,050

(KPa)

1740±290

Ultimate Strain

24±4 /
90±10

30±4 / 19.4±3.91

(%)

18.35±7.61

Modulus of

1320±930 /

1950±150 /

16,050±2,020

15,340±3,480

70±10
Elasticity (KPa)

5.3.2 Effect of Fiber Length and Fibers/Scaffold Mass Ratio on Scaffold
Mechanical Properties
Local and overall mechanical properties of fiber-reinforced scaffolds can be
influenced by fiber content, fiber length, fiber mechanical properties and fiber
distribution. Thus, the effects of varying fiber/scaffold mass ratio and fiber length and
mechanical properties were studied in order to characterize the response of overall
scaffold properties to these parameters. Representative stress-strain curves for a
reinforced scaffold (2 mm fibers at 0.4 fiber/scaffold mass ratio) and an unmodified
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chitosan scaffold are shown in Figure 5. Scaffold reinforced with fibers at 0.4 fiber/
scaffold mass ratio has higher strength, elasticity and stiffness compared to unmodified
scaffold.
200

Fiber-Reinforced Scaffold w/ 0.4 Ratio
Unmodified Scaffold

Stress (kPa)

150

100
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0
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0.7
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Figure 5: Stress-strain curve of reinforced scaffold at 0.4 fiber/scaffold mass ratio and
unmodified chitosan based scaffold. Reinforced scaffold had a higher strength and
strain values compared to unmodified scaffolds.

Scaffolds reinforced with 2 mm fibers showed significant improvement in strength
and stiffness (Figure 6 A, B) as fiber/scaffold mass ratio increased. A 3-fold
improvement in scaffold strength (to 139 kPa) and stiffness (to 0.36 MPa) were
achieved at the 0.4 mass ratio.
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Figure 6: Effect of fiber/scaffold mass ratio on scaffold (A) Strength and (B) Stiffness.
(n=7), all values were statistically different from unmodified scaffold.

Reinforced scaffolds with longer (10 mm) fibers showed lower strength and
stiffness values (comparable to control) when compared to reinforced scaffold with the
shorter (2 mm) fibers (Figure 7 A, B). Since fiber properties were independent of length,
the higher scaffold mechanical properties obtained with shorter fibers were believed to
be due to differences in fiber alignment and the homogenous distribution within the
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scaffold, and possibly a reduced effect of fiber defects with shorter fibers. We also
suggest that with shorter fiber, the defects are less than those found in the longer fibers.
These defects are weak points within the fiber structure and do not provide any
mechanical support to the scaffold.
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Figure 7: Effect of fibers length on chitosan (A) strength and (B) stiffness. * indicate a
statistical difference (p<0.05). (n=7)
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5.3.3 Effect of Fiber Reinforcement on Chitosan-Based Heart Valve Scaffolds
In order to examine the effectiveness of fibers on improving scaffold properties in
more complex geometries, fiber-reinforced heart valve scaffolds were fabricated at a
fiber/scaffold mass ratio of 1.0. Reinforced heart valve scaffolds showed significant
improvements in strength and stiffness at the leaflet, sinus and cylinder as shown in
Figure 8. At the leaflet, a 4-fold improvement in strength from 50 to 220 kPa was
achieved (Figure 8 A) along with a 6-fold improvement in stiffness from 0.07 to 0.4 MPa
(Figure8 C). Sinus strength and stiffness improved 2-fold. Likewise, a 2-fold
improvement in strength and stiffness was achieved at the cylinder. The improvements
correlated with a reduction in maximum strain (Figure 8 B). The major reduction
occurred at the leaflet and cylinder. Leaflet maximum strain was reduced from 0.9 to
0.58 while cylinder maximum strain reduced from 1.3 to 0.25. Different fibers mass
fractions were distributed according to the importance of structure in the valve. More
fibers mass fraction was given to leaflet, which is the major component of the valve,
followed by the sinus, which is a crucial part of the valve and important for valve
function, and the least was for the cylinder. The only statically differences in strength,
elasticity and stiffness values for the unmodified scaffolds were between the leaflet and
the cylinder or sinus due to the pore size variations of the scaffold. There was no
statistical difference in strength, elasticity and stiffness values for the unmodified
scaffold between the cylinder and the sinus.
Table 4 shows mechanical properties of reinforced heart valve scaffolds
compared to human pulmonary and aortic valves. Leaflet strength (220 kPa) was near
comparable to the radial properties of the human pulmonary (290 kPa) and aortic (320
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kPa) heart valves. Minimum leaflet stiffness (260 kPa) was near comparable to the
minimum value of the pulmonary valve (390 kPa). Reinforced scaffold had also a near
comparable elasticity values to both human valves. However, the improved properties of
the valve scaffold are still lower than the properties of the aortic and pulmonary valves
in the circumferential direction.
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Figure 8: Reinforced heart valve scaffold with 2mm fibers length at 1.0 fiber/scaffold
mass ratio showing (A) Strength, (B) Maximum Strain and (C) Modulus of elasticity.
Values were statistically different at each location between the two conditions (p<0.05).

5.3.4 Partial Dissolution of Chitosan Fibers within Chitosan Scaffold
Partial fibers dissolution occurred to the embedded chitosan fibers due to the
acidic nature of chitosan solution forming the scaffold. Although, both phase contrast
and SME images (Figure 9 A, B) showed that fibers were present within the matrix; lack
of fibers in some areas with the scaffold suggested the partial dissolution of fibers. We
further confirmed the fibers dissolution by immersing chitosan fibers in 1 vol% acetic
acid concentration. Complete fibers dissolution by loosing fiber structure and forming
hydrogels within half an hour of immersion was observed. However, fibers dissolution
was minimized in the experiments through quick freezing of scaffold after fibers
embedding. Based on these findings, it was proposed that further improvement of
scaffold mechanical properties can be achieved if fibers dissolution is prevented. The
working hypothesis for this experiment is that immobilizing heparin onto chitosan
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fibers would prevent dissolution of chitosan fibers and further improve scaffold
mechanical properties. The following section will provide more details on the effect of
heparin covalent crosslinking onto chitosan fibers on the fibers mechanical properties.

Figure 9: Reinforced scaffolds with chitosan fibers. (Left) phase contrast image of
transverse section of scaffold showing the embedded chitosan scaffold were present
within the matrix, scale bar 250µm and (Right) transverse section SEM image shows
porous chitosan scaffold with fibers embedded, scale bar is 100 microns

5.3.5 Effect of Heparin Immobilization on Chitosan Fibers Mechanical Properties
Since observations indicated that chitosan fibers embedded in a chitosan
solution exhibited swelling and loss of defined structure, crosslinking was considered as
a method of stabilizing fibers in the acidic solution environment. Heparin can function as
a multi-valent crosslinker for chitosan materials by using carbodiimide chemistry to
generate intermolecular amide linkages. Heparin can also contribute useful biological
properties to a biomaterial. It was hypothesized that preventing fiber dissolution via
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crosslinking

would

further

improve

scaffold

mechanical

properties.

Covalent

immobilization of chitosan fibers with heparin produced a significant increase in fiber
diameter from 325 µm to 500 µm due to fibers swelling (Figure 10 A). Heparin-chitosan
fibers had lower strength and stiffness values when compared to unmodified chitosan
fibers. Fiber strength decreased from 0.7 MPa to 0.3 MPa after immobilization (Figure
10 B), while a slight improvement in breaking strain from 0.15 to 0.2 resulted from
heparin immobilization (Figure 10 C). Fiber stiffness (Figure 10 D) was also reduced
from 3.6 MPa to 1.6 MPa. A dissolution study of heparin-chitosan fibers showed that
fibers did not dissolve for up to 24 hours when immersed in acidic solution.
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Figure 10: Effect of crosslinking of chitosan fibers with heparin on fibers (A) diameters,
(B) strength, (C) elasticity and (D) stiffness. (n=10)

5.3.6 Effects of Fiber Crosslinking and fiber mechanical properties on Scaffold
Mechanical Properties
Despite the reduced mechanical properties of the heparin-immobilized fibers,
scaffolds reinforced with heparin-chitosan fibers showed a significant improvement in
strength and stiffness as fiber/scaffold mass ratio increased (Figure 11). At a 0.4
fiber/scaffold mass ratio, strength improved 2-fold from 40 to 80 kPa (Figure 11 A).
Likewise stiffness also improved 2-fold from 0.08 to 0.16 MPa (Figure 11 B). This
improvement confirmed our hypothesis that improvement can be achieved even with
fibers that have below optimal mechanical properties. Moreover, these finding
suggested that the mechanical properties of fibers can greatly influence the mechanical
properties of the reinforced scaffold.
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Figure 11: Effects of chitosan fiber and modified heparin fiber mechanical properties on
scaffold (A) tensile strength and (B) modulus of elasticity. Error bars indicate standard
deviation from 7 samples. Values at each mass ratio for the two conditions were
statistically different except for tensile strength at a ratio of 0.2.
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5.4

Discussion
While chitosan is being widely studied as an implant material for regenerative
medicine and tissue engineering, relatively low mechanical properties have limited its
application in load-bearing situations. On the other hand, recent results hint that low
stiffness may actually play a role in defining materials with favorable tissue responses
and high biocompatibility (Engler et al., 2006; Dikovsky et al., 2008; Dado and
Levenberg, 2009; Suzuki et al., 2010). Thus, maintaining low surface stiffness while
increasing bulk strength and stiffness may be a key to improve chitosan’s broad utility
while maintaining its desirable biological properties.
The composite approach employed in this study allows the inclusion of higher
strength chitosan fibers which favorably increase the overall material properties, while
retaining the low stiffness of the embedding chitosan matrix. It is the embedding matrix
which provides the majority of the scaffold contact area, and thus determines the cell
and tissue response.
Fabrication of scaffolds from chitosan solutions using the freeze-drying technique
is a diffusion-limited process that can be expected to generate a relatively low
crystallinity matrix. This amorphous structure yields substantially lower mechanical
properties than those obtained using slower evaporative methods or strong bases, both
of which generate chitosan films with higher crystallinity (Suh and Matthew, 2000). As
with other polymeric materials, forming chitosan fibers by extrusion produced a material
with higher strength and stiffness. These property increases are direct result of two
phenomena. First the extrusion introduces a degree of molecular alignment due to flow.
Secondly, the extrusion into a base both immobilized the molecular organization by
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gelation, and also compacted the molecular structure and increased crystallinity by
rapid extraction of protons from the cationic polymer. The net effect of increased
molecular alignment and crystallinity yields to higher mechanical properties (Notin et al.,
2006). Chitosan fibers produced using this technique had smooth surfaces consistent
with previous reports (Tuzlakoglu et al., 2004).
The mechanical properties of chitosan fibers produced by gelation techniques
have been studied previously. However, properties have varied widely depending on:
chitosan degree of deacetylation and molecular weight, concentration in solution,
solvent type, fiber diameter and hydration state, coagulation solvent type, and pH
(Hirano and Midorikawa, 1998; Knaul et al., 1999; Lee et al., 2007). This wide range of
variable parameters hindered direct comparison. However, the strength of our fibers
was comparable to those values of chitosan fiber produced by wet spinning under the
same condition by Notin and colleagues (Notin et al., 2006).
The high mechanical properties of chitosan fibers exceeded those of the native
valve tissue which may involve introducing material with less desirable biological
properties if used alone to fabricate a non-woven mesh scaffold (Stradins et al., 2004).
The reinforced scaffold showed a continuous improvement in strength and stiffness up
to at least a 0.4 fiber/scaffold mass ratio. With higher mass ratios, scaffold strength and
stiffness decreased, a finding that is consistent with Wang et al (Wang et al.,
2009).Wang et al similarly demonstrated a maximum in compressive modulus up to a
0.4 fiber/scaffold mass ratio when chitosan fibers were used to reinforce PLLA nanofibrous scaffolds. Above 0.4 ratio, compressive modulus decreased.
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Fiber length was also shown to greatly affect the mechanical properties of our
scaffolds. Shorter fibers may be expected to provide a more homogenous distribution
throughout the scaffold due to the ease with which they can redistribute during the
solution freezing process. Furthermore, shorter fibers are more likely to align with the
pore walls and thus contribute more of their strength to the pore wall in which they are
embedded. Additionally, defects generated in fibers during formation can adversely
affect the mechanical properties of longer fibers, since each fiber may have several
defects. Such defects within a long fiber can adversely affect scaffold properties some
distance away from the actual defect site. Shorter fibers will intrinsically have fewer
defects per fiber and cannot transmit the effects of a defect to distant locations. In
addition to the effect of short fibers on scaffold mechanical properties, we also believe
that producing chitosan fibers with small diameter will improve their mechanical
properties. Despite that we did not explicitly investigate that effect of reducing fiber
diameter on fiber mechanical properties; however, we still have shown the covalent
immobilization of chitosan fibers with heparin increased fiber diameters. This increase in
diameter correlated to an increase in fiber strength and stiffness as shown in Figure 10.
These results support the fact that the reduction in fiber diameters will improve the fiber
mechanical properties. This improvement in fiber mechanical properties will improve the
overall scaffold properties
Reinforcing actual heart valve scaffolds with this method improved strength and
stiffness and reduced scaffold elasticity. The improved strength and elasticity values
were comparable to the radial directions of native aortic and pulmonary valves. The
fiber-reinforcement significantly improved valve scaffold stiffness but not to a closer
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stiffness value of the native valves. The percentage of improvement was found to vary
with location in these structured scaffolds. In addition to the differences in fiber/ scaffold
mass ratio, the variation with location was likely due to differences in fiber alignment
with the local scaffold plane. Since the 2 mm fibers were randomly oriented in the
chitosan solution, the degree of fiber alignment achieved in particular scaffold region
would be expected to vary with the thickness of the scaffold region, as well as the
freezing conditions and the resultant porosity and pore orientation of that region. Since
the valve leaflets were the thinnest scaffold component, they exhibited the greatest fiber
alignment with the local plane and hence the greatest percentage improvement in
properties. Changes in fiber distribution during mold assembly and loading may also
have played a role. Moreover, quantifying the orientation of the fibers would effectively
explain the effect of fiber orientation on scaffold mechanical properties.
Covalent crosslinking of chitosan hydrogels produces a permanent network
structure that resists dissolution at the low pH conditions at which chitosan is normally
soluble (Berger et al., 2004). Heparin was specifically chosen as a crosslinking agent
due to its useful biological properties including growth factor and matrix protein binding
(Lindahl and Hook, 1978). Previously, Uygun et al (Uygun et al., 2009) showed that
among six glycosaminoglycans (GAGs) studied, MSC growth rate was highest on
immobilized heparin. Given the known swelling of chitosan fibers when mixed into an
acidic solution, it was hypothesized that covalent crosslinking of chitosan fibers with
heparin would minimize fiber swelling and strength loss during reinforced scaffold
preparation. Additionally, literature suggested that crosslinking different forms of
hydrogels with heparin by soaking may result in a highly crosslinked surface(Mi et al.,
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1997). This surface crosslinking ultimately inhibits the crosslinker from diffusion to the
core of the hydrogel. This may explain the increase in fibers diameter upon crosslinking.
(Mi et al., 1997; Shu et al., 2001).
Covalent and ionic immobilization of GAGs on chitosan substrates or fibers have
been investigated previously (Madihally et al., 1999; Madihally and Matthew, 1999; Cho
et al., 2008), however, insufficient information was provided regarding the mechanical
properties of immobilized constructs. In this study we showed that immobilization of
chitosan fibers with heparin reduced their strength and stiffness. We observed similar
trend for other GAGs such as dermatan sulfate and chondroitin 4-sulfate (data are not
shown). Since the crosslinking occurs with chitosan amino groups that would normally
be involved in hydrogen bonding, the reduction in fiber mechanical properties may be
due to reductions in chitosan crystallinity caused by the elimination of some inter-chain
hydrogen bonds. This phenomenon would also account for the increase in fiber
diameter as the reduced crystallinity and physical crosslinking would result in increased
swelling of the hydrated fiber matrix. Moreover, from a stress point of view, the increase
in fibers diameters resulted in a larger cross-sectional area. This increase in crosssectional area decreases the stress. Fan et al recently showed that chitosan scaffold
stiffness decreased when crosslinked with galactosylated hyaluronan, a finding that is
consistent with our results (Fan et al., 2010). Despite this reduction in fiber mechanical
properties, the heparin-modified fibers still improved the mechanical properties of the
reinforced scaffolds, but to a lesser extent to the unmodified fibers. This confirms that
the mechanical property improvements are directly correlated to the mechanical
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properties of the embedded fibers and are not simply the result of an effective increase
in chitosan solution concentration.

5.5

Conclusions and Future Work
In this chapter, the feasibility of improving the mechanical properties of chitosan
scaffolds by embedding chitosan fibers within the scaffold has been demonstrated. The
ability to control the degree of mechanical property improvement was shown by
adjusting three major factors; the fiber/scaffold mass ratio, fiber length and fiber
mechanical properties. The methods described here broaden the range of chitosan
scaffold mechanical properties and thereby increase the usefulness of this biomaterial.
It was also shown that embedded chitosan fibers improved scaffold mechanical
properties; however, further improvement is needed. Scaffold mechanical properties
can be further improved through the improvement in fiber mechanical properties as it
was shown that fiber mechanical properties greatly affect the degree of scaffold
improvement. The next chapter will discuss different chemical and physical treatments
that were used to increase fiber mechanical properties. Fiber distribution within the
scaffold should be quantified to better evaluate the effect of fibers on scaffold.
Moreover, achieving a better fiber distribution and alignment similar to the collagen and
the fibrin fibers within the native valve leaflet is also believed to further improve the
scaffold mechanical properties specifically in the circumferential direction.
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CHAPTER SIX
IMPROVING CHITOSAN FIBER MECHANICAL PROPERTIES THROUGH PHYSICAL
AND CHEMICAL TREATMENTS
6.1

Introduction
Chitosan, the principal derivative of chitin, is a linear polysaccharide that is

considered the second most abundant natural polymers after cellulose (Madihally et al.,
1999; Suh and Matthew, 2000). Due to its attractive biocompatibility, low toxicity and
biodegradability properties, currently chitosan is widely investigated as potential
biomaterials for different biomedical and bioengineering applications.
One of the main concerns with using chitosan hydrogel is the low to moderate
mechanical properties of its scaffold, fibers or cast membranes (Wei et al., 1992).
Several approaches have been proposed to improve its mechanical properties using
physical treatments or chemical modifications.
Chemical modification attained a great attention from researchers than physical
treatments due to the variety and the wide possibilities that can be done through the
numerous amino and hydroxyl side groups. In general, chemical modifications, intended
to improve the mechanical properties of chitosan fibers, usually applied after fibers are
formed and dried. However, recent studies showed that chemical modification may
result in reducing mechanical properties of fibers (Hirano et al., 1999). In contrast,
another study showed that mechanical properties of chitosan fibers can be improved
through immersion in a separate solutions of phosphate and phthalate ions (Knaul et al.,
1999). When chitosan fibers crosslinked with epichlorohydrin, mechanical properties of
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wet fibers significantly improved as reaction time and temperature increase (Wei et al.,
1992).
Physical treatments to improve mechanical properties of chitosan membranes
through annealing showed an improvement in membranes ductility (Kolhe and Kannan,
2003). However, studies which were performed to evaluate the effect of either chemical
modifications or physical treatments on the mechanical properties of chitosan fibers in
particular are insufficient and inconclusive.
Chitosan fibers have been used in different tissue engineering applications to
reinforce scaffolds (Li et al., 2006; Li et al., 2009; Wang et al., 2009). Recently, chitosan
fibers have been introduced as a reinforcement method to improve scaffold mechanical
properties (Wang et al., 2009). In the previous chapter, the utility of chitosan fibers to
reinforce chitosan-based scaffold was demonstrated. It was also shown that the
mechanical properties of chitosan fibers influence the degree of scaffold improvement.
Scaffold reinforced with stronger fibers were shown to have higher strength and
stiffness values compared to scaffold reinforced with weaker fibers. The working
hypothesis for this study is that improving the mechanical properties of chitosan
fibers will further improve chitosan based heart valve scaffold. The scope of this
chapter focuses on improving the mechanical properties of chitosan fibers through
various chemical or physical treatments. This improvement in fiber mechanical
properties will produce to a heart valve scaffold with more improved mechanical
properties in the radial and the circumferential directions. As it was mentioned in the
previous chapter, the fabrication of chitosan fibers involves three main parameters
which control fiber mechanical properties and these parameters are: (1) the acetic acid
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concentration which is used to dissolve the chitosan, (2) the pH of coagulation bath
solution that is used to form the hydrogel fibers and (3) the drying temperature (i.e.
annealing). The main aim of this study is to evaluate the effect of these three
parameters on fiber mechanical properties.

6.2

Experimental Work

6.2.1 Materials and Methods
High molecular weight (HMW) chitosan from crab shells with molecular weight of
450 KDa with 75-85% degree of deacetylation was purchased from Sigma-Aldrich (St.
Louis, MO). All other chemicals and solvents were of analytical reagent grade.

6.2.2

Fabrication of Chitosan Fibers Using Polymer Fiber Extrusion Technique
Chitosan fibers were produced using polymer fiber extrusion technique as

mentioned in the previous chapter. Briefly, powder of polymer was dissolved in certain
concentration of a low pH acid solution and then extruded directly into a coagulation
bath contains high pH basic through a Teflon catheter. After neutralizing, fibers are
dried under tension at room temperature.
In this experiment, chitosan solution was prepared by dissolving 1.5 wt. % HMW
chitosan powder in different volume concentrations of acetic acid (AA) (1, 2, 3 and 6
vol%). Chitosan solution was then extruded directly into two different weight
concentrations of ammonia solution (10 and 25 wt%) through 26 gauge (0.45mm
diameter) Teflon catheter. Fibers were then dried (i.e. annealed) under tension at
different temperatures in a lab oven (40, 90, 140 and 195 °C) for 15 minutes and then
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cooled down slowly at a rate of 1C min-1. For all experiments, chitosan solution was
extruded through a syringe pump at a constant rate of 85 ml.hr-1. Chitosan fibers made
of 1.5 wt% chitosan dissolved in 1 vol% of AA and extruded in 10 vol% ammonia
solution and dried under tension at room temperature were used as a control for all
experiments. To further improve chitosan fiber mechanical properties, the effect of
multiple parameters were combined and evaluated.

6.2.3

Measurement of Fiber Diameters
After drying under tension at room temperature, fibers, which were prepared by

varying AA concentration, ammonia solution concentration and drying temperatures,
were fully rehydrated in phosphate buffer saline (PBS). Phase contrast images of wet
fibers produced by different conditions were captured using Nikon DIAPHOT 300
microscopy controlled by HPS-SCSI software (Hamamatsu Corporation, NY, USA).
Diameters were measured using sigma scan pro image analysis software (SPSS Inc.,
Chicago, IL) and the average was calculated for each condition from 40 measurements.

6.2.4

X-Ray Diffraction (XRD) Analysis of Fiber Microstructure
Crystallinity of wet chitosan fibers produced by different conditions were

evaluated using rigaku smart lab model X-diffractometer in which a high intensity
monochromatic Ni-filtered Cu Kα radiation was generated at 40 kV and 200 mA.
Scanning was done at 3 degrees min−1 with a step size of 0.25. Graphs of intensity
versus 2-theta were plotted for ammonia concentration and annealing experiments. For
annealing experiment, more analysis was conducted by plotting the peak height ratio of
crystalline to amorphous peaks against the temperature. Height peaks was evaluated
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by averaging the intensity of ± 5 degrees around the corresponding crystalline or
amorphous peak.

6.2.5

Evaluating the Mechanical Properties of Chitosan Fibers
For each experiment, mechanical testing was conducted on wet fibers (n=15)

using 100N Bionex monotonic tensile testing machine. Fiber diameters were fed
manually to a user interface software TestPad v 1.0 when mechanical testing was
conducted. Fibers were mechanically tested by setting gauge length to 20mm and
speed to 20mm/min. Maximum stress, breaking strain and modulus of elasticity at a
strain rate of 2% were evaluated for all samples and average values were plotted
against each investigated condition.

6.2.6

Statistical Analysis
Statistical analysis of data on fiber diameters and mechanical properties was

performed using one way student’s t-test with a 95% confidence limit. Data were
presented as mean ± SD.

6.3

Results

6.3.1 Effect of Acetic Acid Concentration on Chitosan Fibers Mechanical
Properties
The working hypothesis for this experiment is that increasing the concentration
of acetic acid to a certain value in chitosan solution will form chitosan fibers with
improved microstructure and mechanical properties. Increasing acetic acid
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concentration increased fibers diameters as shown in Figure 12 A, however a slight
decrease was observed in fibers diameters at 2 vol% AA.
Mechanical properties of fibers showed approximately 2fold improvement in
fibers strength from 0.7 to 1.2 MPa when 2 vol% of AA was used (Figure12 B). As the
concentration of AA increases beyond 2 vol%, strength of fibers decreased gradually to
be around 0.9 MPa at 3 vol % of AA. However, when 6 vol % of AA was used to
dissolve the chitosan, fibers strength decreased by 2fold from 0.7 to 0.3 MPa (Figure12
B). Increasing AA concentration resulted in decreasing the fibers elasticity slightly and
was significant when AA concentration exceeded 2 vol% (Figure 12 C). Fibers stiffness
improved by 2fold from 3.5 to 7 MPa as the AA concentration increased up to 3 vol%
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Figure 12: Effect of acetic acid (AA) concentration on chitosan fibers (A) diameters, (B)
strength, (C) elasticity and (D) stiffness.

6.3.2 Effect of Coagulation Bath pH of Ammonia Solution on Chitosan Fibers
Mechanical Properties
Coagulation bath that contains strong base is usually used to produce hydrogel
polymer fibers. It was hypothesized that increasing the pH of the coagulation bath
will cause a more organized fiber microstructure and improve the mechanical
properties of chitosan fibers. To do so, the concentration of ammonia solution in the
coagulation bath from 10 wt% up to 25 wt% was increased. Results showed that
chitosan solution extruded in 25 wt% ammonia solution resulted in reducing chitosan
fiber diameters from 352 to 286 µm as shown in Figure 13 A. This reduction in fiber
diameters suggests formation of fibers with more crystalline structure and improved
mechanical properties. To further confirm these findings, XRD test was conducted. XRD
spectra of wet chitosan fibers showed 2 dissimilar peaks as shown in Figure 13 B (Lee
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et al., 2004). The first peak is a sharp and intense peak at 2θ=21° which represents the
crystalline region. The second peak is less intense and broader than the first peak at
2θ=27° which represents the amorphous region (Uygun et al., 2010). With higher
ammonia concentration, the crystalline peak is higher compared to the lower ammonia
concentration. Additionally, the peaks height ratio of crystalline/amorphous peaks (i.e.
2θ21/2θ27) was higher for fibers coagulated in 25 wt% ammonia solution. This confirms
that the crystalline fraction is the principal structure in the fibers which were extruded in
higher ammonia solution. This crystalline structure (i.e. compact structure) makes the
fibers more hydrophobic and resisting swelling upon hydration, a phenomena that
explains the reduction in fiber diameter. Moreover, this crystalline structure suggests
improvement in fiber mechanical properties. The XRD spectra shown in Figure13 B
confirmed this hypothesis and showed a higher crystalline (2θ=20°) to amorphous peak
(2θ=27°) for fibers extruded in higher ammonia solution.
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Figure 13: Effect of coagulation bath of ammonia solution, (A) chitosan fibers diameters
and (B) XRD spectra of chitosan fibers extruded in 10 or 25 wt% ammonia solutions. (*
p<0.05)

Mechanical testing results further confirmed our as fiber strength improved by
2fold from 0.7 to 1.2 MPa as shown in Figure 14 A when higher concentration of
ammonia solution was used. Fiber elasticity decreased by 2fold from 0.2 to 0.09 when
chitosan extruded in higher concentration of ammonia solution as shown in Figure 14 B.
Extruding chitosan solution in higher ammonia concentration resulted in a significant
improvement in fibers stiffness with 4fold increase from 3.5 to 13 MPa as shown in
Figure 14 C. The mechanical results confirmed our hypothesis that with higher ammonia
concentration, the crystalline fraction is dominant in fibers microstructure.
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Figure 14: Effect of coagulation bath ammonia solution on chitosan fibers mechanical
properties, (A) fiber strength, (B) fiber elasticity and (C) fiber stiffness.

6.3.3 Effect of Drying Temperature on Chitosan Fibers Mechanical Properties
Drying fibers under tension at high temperature helps in reforming the
microstructure of fibers. It was hypothesized that annealing of chitosan fibers (drying
temperature) will form more organized microstructure and improve fibers
mechanical properties. Different temperatures were studied as drying temperatures
and results were compared to fibers dried at room temperature.
Measurement of diameters revealed a reduction in fibers diameters as drying
temperature increased. The reduction in fiber dimension was mostly significant after
90°C as shown in Figure 15. This reduction in fibers di ameters suggested that fibers are
hydrophobic and resist swelling due to the crystalline microstructure.
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Figure 15: Effect of drying temperature on chitosan fiber diameters

XRD spectra of chitosan fibers annealed at different temperatures shown in
Figure 16 A revealed distinct peaks: two amorphous peaks were present at 2θ=9° and
27° and crystalline peak at 2θ=21°. Chitosan fibers that were dried at room temperature
had a broader and less sharp crystalline peak. Also, the second amorphous peak was
much broader compared to the same peak in different annealing temperatures. This
suggests a less organized microstructure and lower mechanical properties. Figure 16 B
shows the height ratio of the crystalline peak to the second amorphous peak (2θ21 /
2θ27). The height ratio increased as the annealing temperature increased indicating that
the microstructure is moving toward the crystalline structure. The increase in the
crystalline structure causes an improvement in mechanical properties due to the
organized structure. A significant increase in the height ratio at 40C was observed
which is due to the phase transition that chitosan was undergoing around this
temperature (Goycoolea et al., 2007).
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Figure 16: XRD spectra of chitosan fibers annealed at different temperature (A) and
height ratio of crystalline to amorphous peaks (B)

Mechanical properties of annealed fibers showed that fibers strength improved
as temperature increases as shown in Figure17 A. A significant 3fold improvement of
fibers strength was obtained at 195°C. Fibers elasticity slightly improved when
temperature increased up to 90°C and then decreased t hereafter to be the minimum at
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195°C as shown in Figure 17 B. Fibers stiffness improved with increasing the
temperature to be significant after 90°C with 8fold improvement in fibers stiffness at
195°C as shown in Figure 15 C). The improvement in a nnealed fibers mechanical
properties was consistent with the XRD results which showed that increasing
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Figure 17: Effect of annealing temperature on (A) chitosan fibers strength, (B) fibers
elasticity and (C) fibers stiffness.

6.3.4 Effect of Combined Parameters on the Mechanical Properties of Chitosan
Fibers
As it was shown in the proceeding sections in this chapter, individual parameters
improved fiber mechanical properties. In this study, the aim is to combine these
individual parameters to seek further improvement in fiber mechanical properties. Figure
18 shows representative stress-strain curves of chitosan fibers with different parameters
combination.
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Figure 18: Representative Stress-Strain curve of different chitosan fibers formed
with combined parameters

Figure 19 shows the effect of single parameters on chitosan fibers mechanical
properties and the effect of combined parameters. When fibers formed by dissolving
chitosan solution in 2 wt% AA and extruded in 25 vol% ammonia solution, fibers
strength improved 3-fold compared to control fibers (Figure 19 A). Further improvement
in fibers strength was achieved when annealing was combined from 0.07 MPa to 0.42
MPa. A further improvement up to 7-fold from 0.07 MPa to 0.5 MPa was achieved when
fibers immobilized with heparin. Fibers elasticity decreased when one parameter was
investigated (Figure 19 B). When 2 parameters were combined, fibers elasticity was
comparable to the control. However, when 3 parameters or more were combined, fibers
elasticity decreased significantly. In general, fiber elasticity was either comparable to
control fibers elasticity or less. Fibers stiffness improved with all parameters that were

68
investigated (Figure 19 C). The improvement in fibers stiffness was always significant
when fibers are annealed at 195C.
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Figure 19: Effect of combing parameters on (A) fiber strength, (B) fiber elasticity and (C)
fiber stiffness

6.4

Discussion
Chitosan dissolves slowly in acidic pH solution, swells in neutral solution and

precipitates in basic solutions.
When 2 vol% of acetic acid was used to dissolve the chitosan, a reduction in fiber
diameter occurred. This reduction in fiber diameter can be explained by the complete
dissolving of the chitosan particles within the solution. A complete dissolving will results
in forming chitosan fibers with more crystalline structure. However, when acetic acid
concentration was increased, fiber diameters were increased. The excess amount of
acetic acid causes polymer protonation for the chitosan. This protonation and increase
in hydrogen bonding tends to form a loosely-packed and extended structure. This
extended structure is more hydrophilic and amorphous. This explanation was confirmed
by the mechanical properties results. The results showed that the strength increased
when 2 vol% of acetic acid was used and then decreased as the acetic acid
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concentration decreased. Moreover, the elasticity of the fibers decreased significantly
after 2 vol% of acetic acid.
Lee and colleagues showed that increasing sodium acetate concentration in
NaOH coagulation bath increases fibers tenacity and modulus of elasticity as
coagulation solution’s pH increases (Lee et al., 2007). This finding was consistent with
our findings that increasing the concentration of ammonia solution (i.e. increasing the
pH) improved fiber mechanical properties.
Most of mechanical properties and XRD peaks changes (Figures 13 and 14)
occurred around 90C. Several quite different glass transition temperatures of chitosan
have been reported (150C, 161C and 203C) (Scandola et al., 1991; Sakurai et al.,
2000; Ahn et al., 2001). A recent study attempted to determine the glass transition
temperature (Tg) of chitosan films using four methods including differential scanning
calorimetry (DSC)(Dong et al., 2004). It has been reported that the first heating run
showed an endothermic peak around 100 °C while the second heating run confirmed
the Tg to be between (140-150 °C)(Dong et al., 2004). The first temperature (100 °C)
attributes to absorbance of moisture and the reformation of the microstructure of
chitosan fibers. In our experiment, the decrease in fiber diameters starts to be
significant and to occur around 90C which confirms the reforming of the microstructure.
Additionally, major changes in fibers strength, elasticity and stiffness started to occur
around that temperature also. However, the crystalline structure was dominant in fibers
microstructure around the chitosan Tg which was confirmed by the significant reduction
in fibers diameters and the improvement in fibers strength and stiffness. Phase
transition of chitosan has been reported to occur around 30 °C (Goycoolea et al., 2007).
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In our experiment, we observed major microstructural changes confirmed by the XRD
spectra results shown in Figure 16. Below this temperature, chitosan hydrogel is
swollen, hydrated and hydrophilic, while above it, the hydrogel becomes dehydrated
and hydrophobic. These theories explain the bigger diameter of chitosan fiber before 40
°C and the reduction in their diameters as temperature increase beyond 40 °C. Around
this temperature, chitosan is believed to form glasses before crystallize. This
phenomenon may explain the high crystalline/ amorphous ratio obtained at 40 °C in
Figure 16 B but the low strength and stiffness values shown in Figure 17.
When individual parameters were combined, significant improvement in fiber
strength and stiffness were achieved. This improvement is a result of forming chitosan
fibers with more crystalline structure which resist swelling.
Physical and chemical treatments which were used to improve chitosan fibers
mechanical properties did not affect fiber biocompatibility and supported cell attachment
and proliferation in a short term culture. In Chapter eight, detailed evaluation of fiber
biocompatibility with mesenchymal stem cells will be introduced.

6.5

Conclusions and Future Work
Chemical modification was shown previously to improve fibers mechanical

properties but caused structural changes and potentially result in adverse toxicity effects
which hinder the use of these modified fibers in tissue engineering applications.
Improving chitosan fibers produced through polymer fiber extrusion technique was
demonstrated through physical treatments avoiding any potential major structural
changes or toxicity effects. These findings should expand the use of chitosan fibers with
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improved mechanical properties in numerous tissue engineering applications. Despite
that the effect of these mechanically improved fibers was not evaluated on scaffold
mechanical properties, it is still expected that these improved fibers will provide
additional strength and stiffness to the scaffold.
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CHAPTER SEVEN
ISOLATION, CHARACTERIZATION AND PROLIFERATION OF OVINE BONE
MARROW- DERIVED MESENCHYMAL STEM CELLS: POTENTIAL SOURCE FOR
CARDIOVASCULAR TISSUE ENGINEERING
7.1

Introduction

7.1.1 Bone Marrow-Derived Mesenchymal Stem Cells (MSC)
Human mesenchymal stem cells (hMSCs), which are present in adult bone
marrow, are believed to be multipotents cells (Pittenger et al., 1999). MSCs are a rare
population of adult bone marrow (0.001-0.01%) and their number decreases with age
(Rao and Mattson, 2001). Isolating these cells from peripheral blood and cord blood is
hard due to limited number of cells (Miao et al., 2006). hMSCs have the ability to
replicate as undifferentiated cells and differentiate to various mesenchymal tissue
lineages such as bone, cartilage, fat, tendon, muscle and marrow stroma (Rebelatto et
al., 2008). The ability of a population of mesenchymal stem cells within the bone
marrow to differentiate into bone and cartilage was first suggested by Friedenstein
nearly 40 years ago (Miao et al., 2006) Upon isolating and culturing, MSCs display a
stable phenotype and grow as a monolayer in vitro. Several studies have shown that
MSCs possess the ability to exclusively differentiate upon induction into adipogenic,
osteogenic and chondrogenic lineages (Pittenger et al., 1999; Sutherland et al., 2005;
Rebelatto et al., 2008). MSCs gained a great attention from researchers around the
world mainly because of their therapeutic potential for tissue or organ repair.
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7.1.2 Characterization of Bone Marrow-Derived Mesenchymal Stem Cells
Characterization of multipotency property of MSCs can be demonstrated by three
ways: First, MSCs must be plastic-adhesive and have self-renewal properties when
maintained in standard culture conditions. Second, MSCs must express CD105, CD73
and CD90, and lack the expression of CD45, CD34, CD14 or CD11b, CD79α or CD19
and HLA-DR surface molecules. Third, MSCs must differentiate into adipocytes (fat),
osteoblasts (bone), and chondroblasts (cartilage) in vitro using lineage-specific inducing
media (De Ugarte et al., 2003). However, most recent studies have demonstrated that
MSCs differentiation potential may vary depending on the source (Rebelatto et al.,
2008) and the culture medium supplements (Chase et al., 2010).

7.1.3 Bone Marrow MSCs in Tissue-Engineered Heart Valves Applications
Despite that MSCs can be easily isolated from the bone marrow in animals and
humans, low cells number is still a major limitation for broad study of these cells.
Possible locations in humans and animals are the iliac crest, femur, sternum, fetal blood
and liver, cord blood and in some cases, in adult peripheral blood (Miao et al., 2006).
MSCs can be phenotypically converted into endothelial cells (EC) in vitro by culturing
with 50 ng/ml of vascular endothelial growth factor (VEGF) (Song et al., 2007). MSCs
can also provide a source for fibroblasts/ myofibroblasts and smooth muscle cells
(SMC) (Song et al., 2007; Kurpinski et al., 2010; Song et al., 2010). Recent research
efforts have investigated the potential of bone marrow MSCs to differentiate when
seeded on synthetic heart valve scaffolds (Sutherland et al., 2005). MSCs isolated from
bone marrow were seeded PGA/PLLA nonwoven meshes semilunar heart valve
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scaffolds and statically cultured for 4 weeks and then implanted at the pulmonary valve
position into sheep for 8 months. At the end of the study, MSCs showed the ability to
differentiate into SMC, EC and fibroblasts. The results also showed that histological
structure similar to the native heart valve was obtained.
Another research effort investigated seeding MSCs isolated from bone marrow
on PGA/P4HB composite heart valve scaffolds (Perry et al., 2003). Scaffolds were
cultured for 1 week statically and then transferred to a pulse duplicator bioreactor for 2
weeks. The preliminary results showed patchy surface confluency of cells and deep
cellular material. However, the study did not perform immunohistochemistry studies to
determine the type of the cells which covered and penetrated the surface.
Biomechanical testing showed that the leaflets had a comparable stiffness to the native
heart valve.

7.2

Experimental Work

7.2.1 Isolation of Ovine Bone Marrow Mesenchymal Stem Cells
The protocol developed by DeUgarte and Hedrick for isolating mesenchymal
stem cells from sheep bone marrow was followed with some modification (De Ugarte et
al., 2003). Briefly, Sheep femur bones were collected 4-6 hours after slaughtering from
Saad slaughterhouse, Eastern Market, MI. Femur bones were cut at the epiphyses from
both sides and the bone marrow was extracted as a whole and then cut into small
pieces. 10 ml of DMEM medium added to the bone marrow pieces and then vortexed
for 3 minutes. The mixture was then passed through a 100µm filter. The remaining bone
marrow washed 3 times with medium and the washing medium collected and
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centrifuged for 10 minutes at 2500 rpm. The supernatant was then aspirated and cells
were resuspended in DMEM culture medium supplemented with 10% FBS, 250 µg/ml
amphothericin B (Fungizone) and 0.01 mg/ml Gentamicin. Cells seeded at 2 million
cells/cm2 and cultured, labeled passage zero, maintained at 37°C in 5% CO 2 in air. The
first medium change was done on day 5 of culture after MSCs started to attach. When
cells reached 70% confluency on day 15 of culture, cells were passaged using TrypsinEDTA. Briefly, cells were washed 2 times with warm PBS for 5 minutes each and then
Trypsin was added to the plates and incubated for 10 minutes in the incubator. Trypsin
neutralization was achieved by adding fresh DMEM medium supplemented with FBS to
the plates. Cells were collected and centrifuged for 10 minutes at 2500 rpm and then
the supernatant was aspirated and cells were resuspended in medium and cultured,
labeled passage 1, at low density of 2000 cells/cm2.

7.2.2 Cryopreservation of Sheep Bone Marrow Mesenchymal Stem Cells
MSCs were cryopreserved by deep-freezing in liquid nitrogen after the first
passage until further use. Freezing medium consists of DMEM supplemented with 30%
FBS and 5% Dimethylsulfoxide (DMSO). Cells were detached from the plate surface as
mentioned before. Freezing medium was added to the cells pallet. Cells were
distributed in freezing vials at 500,000 cells/vial and froze for 3 hours in 100%
isopropanol dry ice and then stored in liquid nitrogen.

7.2.3 Characterization of Bone Marrow-Derived Mesenchymal Stem Cells (MSCs)
To characterize the isolated MSCs, a differentiation into chondrogenesis,
adipogenesis, and osteogenesis lineages was conducted. Passage 6 frozen vial was
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cultured in DMEM culture medium supplemented with 10% FBS, 250 µg/ml
amphothericin B (Fungizone) and 0.01 mg/ml Gentamicin. When cells reached 80%
confluency, differentiation experiment was conducted on 2-D dish cultures for the three
lineages. For each lineage, two-duplicate cultures were used and two cultures were
used as a control.
Differentiation of MSCs into Adipocytes
After culturing MSCs for a week in a normal culture medium, adipogenic
differentiation was induced by culturing cells for 3 weeks in adipogenic medium
consisting of DMEM culture medium supplemented with 15% FBS, 0.5 mM isobutylmethylxanthine, 1 µM dexamethasone, 5 µg/ml insulin and 60 µM indomethacin.To
demonstrate that the MSCs differentiated into adipocytes, Oil Red O staining was used
to visualize lipid-rich vacuoles. Briefly, cells were fixed for 60 minutes at room
temperature in 4% formaldehyde and then washed with 70% ethanol. Cells were
incubated in 2% (w/v) oil red O reagent for 5 minutes at room temperature. Excess stain
was removed by washing with 70% ethanol followed by several washes with distilled
water. Counter stained for 2 minutes was then applied using hematoxylin and Eoisin
Staining (HE) to stain the nucleus.
Differentiation of MSCs into Osteocytes
Osteogenic differentiation was induced after 1 week of culturing in normal culture
medium. Cultured cells were induced for 3 weeks of culturing using DMEM culture
medium supplemented with 15% FBS, 0.1 µM dexamethasone, 100 µM ascorbate-2-
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phosphates and 10 mM β-glycerophosphate. The deposition of minerals in experimental
cultures was demonstrated by von Kossa staining.
Differentiation of MSCs into Chondrocytes
Chondrogenic differentiation was induced after 1 week of cell culture in normal
culture medium. Cells were detached using Trypsin and then centrifuged at 300g for 10
minutes in a 15-ml polypropylene tube to form pellet. Chondrogenic differentiation
medium consists of DMEM high glucose (HG) supplemented with 1% FBS, 0.5 µg/ml
insulin, 10 ng/ml TGFβ-1, 50 µM ascorbate-2-phosphate, and 1% ABAM. Medium was
gently overlaid to avoid detaching the cell nodules. Cultures were maintained in
chondrogenic medium for 2 weeks prior to analysis. Safranin O staining was used to
visualize the deposition of protoglycans where Masson’s Trichrome staining was used
to visualize the deposition of collagen type II within the nodules.

7.2.4 MSCs Differentiation into Smooth Muscle Cells (SMC)
Differentiation of MSCs into SMC started immediately at day one of culture by
inducing the differentiation by specific SMC differentiation medium. Differentiation
medium consists of DMEM-HG supplemented with 30% FBS, 1 ng/ml TGFβ-1 and 30
µM

ascorbate-2-phosphates,

while

control

cells

were

grown

in

DMEM-HG

supplemented only with 10% FBS. Differentiation properties were analyzed after one
week of inducing the differentiation. α-smooth muscle actin (α-SMActin) staining was
used to confirm the differentiation of MSCs into SMC using primary antibody, mouse
anti α-smooth muscle actin clone 1A4-Fluorescein isothiocyanate (FITC) (Sigma)
according to the manufacturer protocol. Briefly, cultured MSCs were fixed by incubating
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with 4% formaldehyde solution for 10 minutes at room temperature. The cells were then
washed twice with PBS. The fixed cells were then permeabilized by incubating in 0.2%
Triton X-100 in PBS for 1-1.5 minutes at room temperature and gently rinsed with PBS
four times. Cells were then incubated with blocking solution of 5% non-fat dry milk in
PBS for 30 minutes. Later on, the blocking solution was aspirated off, and the surfaces
were washed with PBS four times. The cells were then stained with primary antibody,
mouse anti α-smooth muscle actin clone 1A4-Fluorescein isothiocyanate (FITC)
(Sigma) at a dilution of 1:250, for 2-3 hrs at room temperature in the dark. To the
existing antibody staining solution, 300 µL of 300 nm DAPI (counter-stain) solution was
added and incubation was continued for another 5 minutes. Later on, the staining
solution was removed and surfaces were washed 5 times with PBS over 30 minutes in
dark. After that, the stained cells were observed under the fluorescence microscope.
Alamar blue assay (Molecular Probes, Invitrogen, CA) was used to evaluate
MSCs proliferation in growth and differentiation mediums according to the manufacturer
protocol. Briefly, alamar blue solution was diluted at 1:10 volume ratio in fresh DMEMHG culture medium and the mixture was then incubated with cells for 4 hours.
Absorbance was read using Perkin Elmer spectrophotometer at 570 nm and normalized
to absorbance readings at 600 nm.

7.2.5 Effect of Serum Concentration on MSCs Proliferation and Attachment
Serum concentration in culture medium almost affects the proliferation of any cell
type due to the components contained in it. To assess the effect of serum concentration
on MSCs proliferation, MSCs at cell density of 10,000 cells/cm2 were cultured in DMEMHG culture medium supplemented with different concentration of fetal bovine serum
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(FBS). FBS concentrations were 1, 2.5, 5, 7.5, 10, and 30%. MSCs cultured in culture
medium without any FBS were used as a control. Additionally, the effect of different
concentrations of FBS in culture medium were compared to proliferation of MSCs
cultured in differentiation medium which contains 30% FBS,1ng/ml of TGF-β1 and 30µM
of ascorbic acid. MSCs were marinated in cultures for 5 days and Alamar blue assay
was used to measure the proliferation rate at day 1, 3 and 5 of culture.

7.2.6 Effect of Immobilized GAGs on MSCs Proliferation and Attachment
The aim of this study was to evaluate the effect of different immobilized GAGs on
chitosan membranes on MSCs proliferation. Heparan Sulfate (MW 10-12 KDa), Heparin
sodium (MW 10-12 KDa) were both purchased from Celsus laboratories, Chondroitin-4Sulfate sodium salt from bovine trachea (MW 20-30 KDa) purchased from Sigma
Aldrich and hyaluronic acid sodium salt (MW 1600-1800 KDa) purchased from
BioChemika-Fluka were covalently immobilized on chitosan membranes as described in
literature (Uygun et al., 2009). Briefly, chitosan solution was air dried in 24 well plate for
overnight. Pre-activated GAGs solution at 1:1 chitosan to GAGs mass ratio was added
to the dry membranes and allowed to react overnight. Pre-activated solution was
prepared by mixing equal volume of EDC solution prepared at a concentration such that
the molar ratio of EDC to GAGs carpoxyls in the reaction mixture was 10:1. Membranes
were then washed with PBS and sterilized with 80% ethanol. MSC of passage 6 were
seeded on different GAGs-Chitosan membranes at 60,000 cells/cm2. Cultures were
maintained in DMEM-HG culture medium supplemented with 1% ABAM and 10% FBS
for 8 days. Phase contrast Images at day 1 and day 3 were taken to observe any
morphological changes in the cultures of different immobilized GAGs. Alamar blue
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(Invitrogen, CA) assay was used according to the manufacturer protocol to quantify
MSC proliferation.

7.3

Results

7.3.1 Isolation of Ovine Bone Marrow-Derived MSCs
MSCs isolated from sheep bone marrow attached well to plastic culture plates as
shown in Figure 20. Cultured MSCs formed a monolayer and had a bipolar to polygonal
fibroblast-like shape. During MSCs culturing, cell proliferation potential increased as the
culture time increased.

Passage Zero, Day8

Passage Zero, Day13

Passage Zero, Day15

Figure 20: Cell attachment and morphology of MSCs at passage 0 during isolation,
Objective is 10X

Subculturing until passage 6 was reached easily to magnify the number of
available MSCs from the same batch for future experiments. Figure 21 shows MSCs of
different passages cultured and grown. Phase contrast images show that subculturing
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did not affect the proliferation potential ot the adhesion capacity of MSCs up to passage
4.

Passage 1, Day 2

Passage 2, Day 2

Passage 3, Day 2

Passage 4, Day 2

Figure 21: Subculturing of MSCs up to passage 4, objective is 10X

7.3.2 Characterization of MSCs
7.3.2.1 MSCs Differentiation into Adipocytes
Figure 22 shows phase contrast microscopy images for control and experimental
cultures captured at different time points. Day 6 shows the beginning of formation of oil
drops in the experimental cultures indicating the starting of MSCs differentiation into
adipocytes. The formation of oil drops continued to form as the culture days increased.
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Control, Day 6

Control,Day 13

Control, Day 20

Experimental, Day 6

Experimental, Day 13

Experimental, Day 20

Figure 22: MSCs differentiation into adipocytes. Formation of oil vacuoles indicating
MSCs differentiation into adipocytes at Day 20, Objective 20X

Adipogenic differentiation was shown by changes in cell morphology which was
then followed by formation of lipids vacuoles during the culture period as seen in Figure
22. However, Oil Red O- stain results did not show that cells stained with oil red stain
despite that the oil droplets were clearly visible with phase contrast microscopy images.
This can be due to the high passage of MSCs that were used (passage 6). Literature
suggested that a lower passage (<3) should be used to differentiate MSCs to
adipocytes (Rebelatto et al., 2008).
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7.3.2.2MSCs Differentiation into Osteocytes
MSCs cultured with osteogenic medium formed colonies as seen in figure 23 at
day 13. The cellular morphology changed from fibroblast-like cells to a cuboidal form as
starting at day 6 of culture and more obvious at day 13 of culture.

Control, Day 6

Control, Day 13

Control, Day 20

Experimental, Day 6

Experimental, Day 13

Experimental, Day 20

Figure 23: Morphological changes in MSCs during their differentiation into osteocytes,
Objective 20X
Figure 24 shows that calcium deposition was present in the experimental cultures
and not in the control cultures. Safranin O was used as a counter stain. Figure 24
shows the tissue culture plates for control and experimental cultures. Experimental
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cultures showed higher amount of nodule formation within the culture. Stain confirms
that MSCs differentiated into osteocytes lineage.

Control

Experimental

Control

Experimental

Figure 24: Von Kossa and safranin-O staining at higher magnification, upper panel, and
the whole culture plate, lower panel

7.3.2.3MSCs Differentiation into Chondrocytes
Figure 25 shows the morphological changes of control and experimental cells. As
the culture goes on, cells in experimental cultures have polygonal shape and start to
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form multiple layers before detachment which are indications of MSCs differentiation
into chondrocytes.

Control, Day 13

Control, Day 20

Experimental, Day

Experimental, Day

13

20

Figure 25: Morphological changes of MSCs during their differentiation into
Chondrocytes, Objective 4X

Figure 26 shows H&E staining that was used to visualize the cells distribution
and morphology within the pellet. Higher magnification of the pellet shows cells stained
blue. Safranin-O staining was used to visualize the deposition of protoglycans within the
pellet. Mason’s Trichrome staining was used to confirm the presence of collagen type II
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which stained blue. These results confirmed the differentiation of MSCs differentiations
into chondrocytes.

H&E
Safranin-O

Masson’s Trichrome

Figure 26: H&E, Safranin-O and Masson’s Trichrome staining confirm the differentiation
of MSCs into chondrocytes

7.3.4 Differentiation of MSCs into Smooth Muscle Cells (SMC)
MSCs differentiation into SMC was induced with higher concentration of FBS and
the addition of TGF-β1 and ascorbic acid to the culture medium. Figure 27 shows that
there was no morphological difference of MSCs cultured in growth medium (referred as
control) and MSCs cultured in differentiation medium (referred as experimental).
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Growth Medium, Day 8

Differentiation Medium, Day 8

Figure 27: Morphological changes of MSCs during differentiation into SMCs, Objective
10X

Staining results for α-SMActin showed that both MSCs cultured in growth
medium and differentiation medium stained for SMC marker. The amount of actin
protein produced by MSCs cultured in growth medium or differentiation medium using
western blot analysis was quantified. Results, as shown in Figure 29, demonstrated that
there was no statistical difference between the amount of actin protein produced by
MSCs cultured in both mediums. Two possible mechanisms might explain why MSCs
cultured in growth medium stained positive with α-SMActin: first, is the effect of
transforming growth factor- β1 (TGF-β1). It has been suggested in literature that 1 ng/ml
of TGF-β1 is sufficient to induce the differentiation of MSCs into SMCs (Narita et al.,
2008). Normally, traditional FBS can contain 16 ng/ml of TGF-β1, so growth medium
which contains 10% FBS may have 1.6 ng/ml of TGF-β1 that was sufficient to induce
the differentiation. The second mechanism is that some MSCs are believed to be
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pericytes (Caplan, 2008). To test the validity of this hypothesis, freshly isolated MSCs of
passage 0 were cultured in DMEM without FBS for one day and stained with α-SMActin.
As shown in Figure 29, MSCs showed expression of α-SMActin which might indicate
that these cells have similar synthetic characteristics to SMC. The two mechanisms will
be discussed in detail in the discussion section in this chapter.

Growth Medium, Day 8

Differentiation Medium, Day 8

Figure 28: α-SMActin staining confirms that both MSCs cultured in growth medium or
differentiation medium differentiated into SMC, Objective 20X
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Fluorescence Intensity
( Amount of Actin Protein)

1.2
1.0
0.8
0.6
0.4
0.2
0.0

Growth(10%FBS)

Diff(30%FBS)

Figure 29: Amount of Actin production in MSC cultured in growth medium or
differentiation medium

Figure 30:α-SMActin staining of MSC of Passage 0 cultured in DMEM culture medium
without FBS for 1 day, Objective 20X
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MSCs proliferation was evaluated for cells cultured in both mediums for 5 days.
In both cultures, results showed that MSCs demonstrated the same growth rate.

Growth Rate ( Day-1)

0.35
0.30

Day 1- Day 3
Day 3-Day 5

0.25
0.20
0.15
0.10
0.05
0.00
Growth(10%FBS)

Diff(30%FBS)

Figure 31: Growth rate of MSC cultured for 5 days in growth medium or differentiation
medium

7.3.5 Effect of Serum Concentration on MSCs Proliferation and Attachment
MSCs cultured with different concentration of FBS showed an immediate
attachment on tissue culture plates as seen in Figure 32. After one day of culture in
different serum concentrations, MSCs attached to the surfaces and spread. It’s likely
that MSCs has high adhesion capacity as they well adhered to the tissue culture plate
when they even cultured in a culture medium without any FBS. There was no clear
morphological changes of MSCs cultured in different concentration of FBS. However,
MSCs showed a different proliferation rate with changing the concentration of the FBS
in the culture medium. The growth rate of MSCs decreased after day 3 when cultured
without FBS in the medium. It’s likely that MSCs proliferation was hindered by that fact
that the culture medium does not have the necessary growth factors for proliferation
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such as transforming growth factor-β1 (TGF-β1), human platelet-derived growth factorBB (PDGF-BB) and basic fibroblast growth factor (bFGF). MSCs cultured in high serum
medium (< 10% FBS) showed higher growth rate compared to the same population
cultured in low serum medium, however, the difference is not remarkable for the same
period of culture. It’s necessary to mention again here that there was no statistical
difference between the growth rate of MSCs cultured in 10% FBS (growth medium) and
differentiation medium. This was consists with the results demonstrated in Figure 31
above.

NO FBS

1% FBS

2.5% FBS

5% FBS

7.5% FBS

10% FBS

Figure 32: Effect of serum concentration in culture medium on MSCs attachment and
spreading, Objective 10X
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Growth Rate ( Day-1)
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Day 1- Day 3
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5
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10

30

Diff

Concentration of FBS (%)
Figure 33: Effect of Serum concentration on MSCs proliferation for 5 days culture.

7.3.6 MSCs Proliferation GAG-Chitosan Membranes
As it appears in Figure 34, all GAGs supported MSC attachment and spreading
from day 1 except on chondroitin-4-sulfate (C4S) surfaces. Upon attachment, MSCs
were elongated and showed spindle shape morphology. MSCs continued to spread and
proliferate throughout the culture period including C4S surfaces. MSCs cultured on
chitosan membranes showed immediate cell attachment and spreading from the first
day of culture.

HS (Day 1)

HS (Day 3)
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Hep (Day 1)

Hep (Day 3)

C4S (Day 1)

C4S (Day 3)

HA (Day 1)

HA (Day 3)

Chit (Day 1)

Chit (Day 3)
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TCP (Day 1)

TCP (Day 3)

Figure 34: Cell morphology of MSC cultured on different immobilized GAGs, HS
(Heparan Sulfate), Hep (Heparin Sodium), C4S (Chondroitin-4-Sulfate), HA (hyaluronic
Acid), Chit (Chitosan) and TCP (Tissue Culture Plate). Objective is 10X.

Normalized Absorbance

2.5
2.0
1.5
1.0
0.5
0.0
HS

Hep

C4S

Surfaces

HA

Chit
Day 3
Day 5
Day 8

Figure 35: Effect of different immobilized GAGs on MSC proliferation for 8 days in static
culture.
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7.4

Discussion
In this study, isolation and characterization of ovine bone marrow-derived

mesenchymal stem cell were demonstrated. Despite the limitation with the number of
MSC that can be isolated from the bone marrow, yet MSCs were isolated in a sufficient
number to conduct the experiments outlined in this chapter and in the following chapter.
As there is no definitive marker to characterize MSCs, usually, MSCs are characterized
by their adhesion capacity and the multipotency ability to differentiate into adipocytes,
chondrocytes and osteocytes. Isolated cells were confirmed to be MSCs using inducing
differentiation medium into the three main lineages. Induced cells showed the ability to
differentiate into the desired population within 3 weeks at maximum.
The differentiation of MSCs into smooth muscle like cells was demonstrated in
this chapter. MSCs stained positive for α-SMActin marker, an early differentiation
marker for smooth muscle cells (SMC). However, it is necessary to mention that MSCs
cultured in either the differentiation medium which contains 30% FBS and 1ng/ml of
TGF-β1 or the growth medium which contains 10% FBS showed positive expression of
α-SMAactin. These findings suggest two mechanisms that might control the
differentiation of MSCs into SMC. The first mechanism is controlled by TGF-β1
concentration in the culture medium. TGF-β1 has been shown previously to induce the
differentiation of neural crest stem cells into SMC (Shah et al., 1996; Chen and
Lechleider, 2004), embryonic stem cells into SMC (Sinha et al., 2004) and adipose
tissue derived stem cells into SMC (Jeon et al., 2006). Narita and colleagues studies the
effect of TGF-β1 on MSCs differentiation into SMC (Narita et al., 2008). In their study, it
was shown that increasing the concentration of TGF-β1 in the culture medium from 0.1
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ng/ml up to 10 ng/ml significantly increased the expression level of smooth muscle
specific genes (α-SMActin, Calponin and SM22). Also, it was concluded in this study
that 1ng/ml of TGF-β1 is enough to induce the differentiation of MSCs into SMC. Actin
protein expression shown in Figure 29 in this chapter demonstrated that both MSCs
cultured in growth medium or differentiation was almost the same. The reason behind
this similarity in protein expression level is due to the FBS. It has been well documented
in the literature that 1 ml of FBS contains up to 16 ng/ml of TGF-β1 (Danielpour, 1993;
Lucia et al., 1998). In the growth culture medium which contains 10% FBS, the
concentration of TGF-β1 can be as high as 1.6 ng/ml. It was well documented in
literature that 1 ng/ml of TGF-β1 is sufficient to induce the differentiation of MSCs into
SMC and increase the gene expression of SMC specific markers (Narita et al., 2008).
This might explain why MSCs cultured in 10% FBS stained positive for α-SMAcin. It was
also shown that concentrations higher than 1 ng/ml of TGF-β1 did not upregulate the
gene expression for all SMC specific markers (Narita et al., 2008). This might explain
why there was no difference in actin protein production in both cultures.
The growth rate of MSC did not change when cultured in growth medium or
differentiation medium. It has been shown before that TGF-β1 provides no significant
enhancement of cell proliferation on its own (Chase et al., 2010). This might explain why
growth rates were not statistically significant.
The second mechanism is that some MSCs are now believed to be pericytes, the
cells that cover the outermost layer of small blood vessels, as MSCs express cell
markers similar to the pericytes (Caplan, 2008). Moreover, this relationship between
MSCs and pericytes was further confirmed by the ability of pericytes to express the
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surface cell markers CD146+, CD34-, CD45-, CD56- and by the subsequent in vitro
differentiation of pericytes into osteogenic, chondrogenic, adipogenic and myogenic
lineage, which are hallmarks for MSC identity (Caplan, 2007). However, MSCs differ
from pericytes as the latter lack the ability to differentiate into hematopoietic or neural
phenotypes in vitro (Kiel et al., 2005). In Figure 31, it was shown that MSC of passage 0
stained positive for α-SMActin after culturing for one day in culture medium without FBS.
This might support that MSCs are pericytes and have similar phonotype to SMC. Ball
and colleagues showed that cultured MSCs had some similar characteristics of
synthetic state vascular smooth muscle cells (SMC) (Ball et al., 2004).
The proliferation assay results of MSCs cultured in different concentrations of
FBS demonstrated that MSCs proliferation increased with increasing FBS concentration
in the medium, however, the difference in the proliferation rate was not remarkable.
Despite that serum does possess a proliferative effect on most cells including MSCs; it
also contains a number of some components which vary from one lot to another.
Moreover, serum components are not even fully known or characterized. As a result,
the use of relatively high concentration of FBS (<10%) in MSCs cultures will definitely
provide inconsistent results in MSCs proliferation and differentiation. Chase and
colleagues recently developed a novel serum-free medium for the expansion of human
mesenchymal stem cells (Chase et al., 2010). DMEM culture medium was only
supplemented with a combination of TGF-β1, bFGF and recombinant human plateletderived growth factor-BB (PDGF-BB). Results showed a significant propagation with
retained phenotypic, differentiation and colony forming potential of human MSCs.
Moreover, Invitrogen has released a reduced serum (2% FBS) with growth supplements
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for MSCs expansion named MesenPRO RS™. According to the product sheet of
MesenPRO RS™ found on the manufacturer website, the new culture medium has
shown 35-45% improvement in MSCs expansion over 4 days of culture compared to
classical culture medium (DMEM supplemented with 10% FBS). The new culture
medium is also capable of marinating the gene expression profile of MSCs and
multipotentiality.
Immobilized GAGs on Chitosan membranes supported MSCs attachment,
spreading and proliferation as shown in Figure 34 and Figure 35. MSCs cultured on
immobilized heparan sulfate surfaces showed slightly higher proliferation rate compared
to other GAGs for the 8 day culture. As heparan sulfate is a highly sulfated GAG, it’s
likely that heparan sulfate has relatively more available ligands for MSC to attach
compared to the other immobilized GAGs. Heparan sulfate is known to act as a low
affinity receptor for variety of ligands including growth factors. It was also shown on
heparan sulfate that the variety in the confirmation and the orientation of heparan
sulfate functional groups allows it to employ different modes of bindings with individual
proteins or protein complex (Gallagher, 2001). Moreover, it has been shown that
heparan sulfate is involved in multiple cell signaling pathways (Turnbull et al., 2001).
This might explain why the proliferation rate on immobilized heparan sulfate was the
highest during the 8 day culture among all studied GAGs. However, before making a
definitive conclusion on the effect of GAGs on MSCs proliferation and differentiation, the
effect of serum in culture medium should be fully understood or an alternative serum
free culture medium should be used to avoid any inconsistency of results.
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It is also worth mentioning that MSCs isolated from ovine bone marrow have a
high adhesion capacity to surfaces in contrast to MSCs isolated from rat bone marrow.
It was shown in Figure 34 that MSCs attached and spread well on chitosan membranes
while rat bone marrow MSCs showed minimal cell attachment and proliferation when
cultured on chitosan membranes (Uygun et al., 2009).

7.5

Conclusions and Future Work
Two mechanisms have been proposed to explain why MSCs have similar

characteristics to vascular smooth muscle cells. The ill-defined and highly variable
nature of traditional serum not only limits the understanding of these mechanisms, but
also MSCs proliferation and multipotentiality. Serum free medium is a practical
alternative for classical culture medium. The use of serum free medium will provide
better understanding of MSCs differentiation into specific cell lineages or the effect of a
tested material or additive.
For the preliminary results introduced in this chapter, it was demonstrated that
MSCs can be isolated from ovine bone marrow and grown in vitro to sufficient numbers
despite the limitation with MSCs number in bone marrow.
GAGs supported MSCs attachment and proliferation and are potential candidates
to be immobilized on chitosan-based scaffolds for improving MSCs proliferation and
potentially their differentiation into a mature tissue. However, other parameters should
be evaluated before deciding on potential GAG such as the deposition of extracellular
matrix proteins in tissues. Also, the effect of GAGs on MSCs differentiation into
endothelial cells (EC) should be evaluated to better decide on one GAG that will support
MSCs proliferation and differentiation in cardiovascular tissue engineering application.
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CHAPTER EIGHT
EFFECT OF STIFFNESS OF MECHANICALLY IMPROVED CHITOSAN FIBERS ON
BONE MARROW- DERIVED MESENCHYMAL STEM CELLS ATTACHMENT,
VIABILITY AND PROLIFERATION
8.1

Introduction
One of the key challenges in stem cells research is to understand how to direct

the differentiation of these cells toward to the desired tissue. Engler and colleagues
pointed out an important factor that regulates stem cells differentiation and determines
their fate: the elasticity of the substrate (Engler et al., 2006). In his research study,
Engler identified that changing the stiffness of the substrate can direct the differentiation
of human mesenchymal stem cells into neuronal, muscle or bone lineages.
Although, the complex interaction between soluble and extracellular matrix
molecules which direct the differentiation of MSC has been studies extensively, the
physical properties of the matrix such as elasticity or stiffness did not gain sufficient
attention in stem cells research (Discher et al., 2005; Vogel and Sheetz, 2006). The
concept behind cell-matrix interaction is that cells use actomyosin contractility for twoway interaction with the matrix (Even-Ram et al., 2006). The contraction of the cell at
integrin-based adhesions will be resisted by the matrix. This resistance will be followed
by the accumulation of additional molecules at these sites. This process results in a
balance of tension force at the cell-matrix interface. Ultimately, the inhibition of myosin
will disrupt this cellular response to the matrix. It’s believed that cellular force-sensing
results in various intracellular signaling (Even-Ram et al., 2006). Others identified some
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increased in intracellular signals molecules such as Rho GTPase and MAP Kinas
activity, which can alter the gene expression and embryonic development and even
tumor cell progression (Paszek et al., 2005; Ingber, 2006; Vogel and Sheetz, 2006).
When MSCs grown on soft, intermediate or hard compliance substrates, the gene
expression of phosphorylated form of neurofilament heavy chain was exclusively
expressed by MSC were grown on soft compliance substrates, while MSCs were grown
on intermediate compliance substrates showed specific expression of myoD and finally
when MSCs were grown on hard compliance substrates showed exclusive expression
of bone CBFα1 (Engler et al., 2006).
The aim of this chapter is to evaluate the effect of fiber stiffness on MSCs
proliferation and attachment. The working hypothesis for this experiment is that
mechanically improved chitosan fibers will improve attachment and proliferation
of mesenchymal stem cells. In chapter six, mechanical properties of chitosan fibers
were significantly improved using different chemical and physical treatments.
Depending on the physical or the chemical treatment or both combined, chitosan fibers
with different stiffness values were generated. These mechanically modified chitosan
fibers with different stiffness values will be used as a substrate for growing MSCs.

8.2

Experimental Work

8.2.1

Fabrication of Mechanically Improved Chitosan Fibers
Chitosan fibers were produced using gel extrusion technique described

previously. Briefly, chitosan solution was prepared by dissolving 1.5 wt% chitosan in 2
vol% of acetic acid. The solution was extruded directly into ammonia solution contains

103
25 wt% ammonium. Four conditions of fibers were tested: (1) fibers dried at 195 ° C and
(2) immobilized with GAGs, (3) fibers dried at room temperature and (4) immobilized
with heparin sodium. Fibers were then cut into small length (<2mm) and sterilized with
80% Ethanol and then washed several times with PBS. Fibers were compacted by
centrifuging to facilitate the handling as one piece and cell culturing and to achieve
better cell to cell contact. A total of 30 mg of fibers for each condition was used.

8.2.2

MSC Culturing and Seeding
MSCs of passage 6 were cultured in DMEM-HG supplemented with 10% FBS

and 1% ABAM for 1 week until cells reached 70% confluency. For each condition,
100,000 cells were seeded on fibers and left for 2 hours in the incubator to allow cell
attachment. After 2 hours, cultured cells on fibers were incubated with DMEM-HG
supplemented with 10% FBS.

8.2.3

MSC Attachment and Viability on Chitosan Fibers with Different Stiffness
Values
MSCs viability and attachment was evaluated through live/dead assay using

Calcein AM (Molecular Probes, Invitrogen, CA) on day 3 and 5 of cultures by following
the manufacturer protocol. Briefly, samples were incubated with DMEM without phenol
red supplemented with 10% FBS which was mixed with 5 µl of calcein AM and 5 µl of
Ethidium homodimer for 10 minutes at 37 °C. Samples were then washed with PBS and
DMEM without phenol red supplemented with 10% FBS was added to the samples.
Samples were then visualized under the fluorescent microscopy using blue filter for live
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cells and green filter for dead cells. Proliferation of MSCs on fibers was evaluated using
Alamar Blue assay (Invitrogen, CA) as mentioned before according to the manufacturer
protocol on day 3, 6 and 9 of the culture. Briefly, alamar blue solution was diluted at
1:10 volume ratio in fresh DMEM-HG culture medium and the mixture then incubated
with cells for 4 hours. Absorbance at 570 nm was read and normalized to absorbance
readings at 600 nm using Perkin Elmer spectrophotometer.

8.2.4

MSCs Cytoskeleton Organization on Mechanically Improved Chitosan
Fibers
Cytoskeleton organization in MSCs that were cultured on mechanically

improved chitosan fibers were investigated by staining the cells for actin fibers with
rhodamine labeled phalloidin (R415, Molecular Probes ,Invitrogen, CA) according to the
manufacturer protocol on day 9 of the culture. Briefly, medium were aspirated and fibers
were washed twice with pre-warmed PBS. Cells were fixed with 4% parafomaldehyde
for 10 minutes and then washed twice with PBS. Cells were then permeabilized with
0.2% Triton X100 in PBS for 5 minutes and then washed twice with PBS. To block
nonspecific binding sites, fibers were incubated with 1% BSA in PBS for 30 minutes at
room temperature and then washed twice with PBS. Fibers were then incubated with 5
μl of rhodamine labeled phalloidin in 200 μl PBS for 20 minutes and then washed twice
with PBS. Cell Nucleus were counterstained with DAPI for 5 minutes and then washed 3
times with PBS, 5 minutes each. Fibers were then imaged with Nikon fluorescence
microscope using ultraviolet (UV) and green filters.

105
8.3

Results

8.3.1 MSCs Viability and Proliferation on Mechanically Improved Chitosan Fibers
Chitosan fibers with different stiffness values are shown in Figure 36. Alamar
blue assay yielded different proliferation rate correlating with the stiffness of the fibers.
MSCs proliferation increased in proportion to fiber stiffness. As seen in Figure 37, the
highest proliferation rate was for the chitosan fibers annealed at 195 °C followed by
fibers annealed at 195 °C and immobilized with hepar in. For the first five days of the
culture, proliferation rate of chitosan fibers dried at room temperature were practically
comparable to the fibers that were dried at room temperature and then immobilized
with heparin despite the difference in fiber stiffness. Moreover, the effect of heparin
immobilization on MSCs proliferation was predominant over fiber stiffness at day 9 of
culture for the first two conditions. Similarly, fibers dried at 195 °C were also nearcomparable to fibers dried at the same temperature but immobilized with heparin
despite the statistical difference in data. Heparin is well known to modulate the growth
factor and the binding proteins which ultimately improve cell attachment and
proliferation. So, the low stiffness value for fibers dried at room temperatures and
immobilized with heparin was compensated with the presence of heparin.
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Figure 36: Stiffness for mechanically improved chitosan fiber
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Figure 37: Alamar Blue results of MSC proliferation for 6 days on different fibers with
different stiffness values.
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Figure 38 shows MSCs viability and attachment on chitosan fibers with different
stiffness values. In all cultures, MSCs attached onto all fibers and started to spread from
the first days of the culture as demonstrated by the cell elongation and presence of
extended cell stress fibers. Moreover, the rate of MSCs viability on all chitosan fibers
were high which confirmed by the minimal presence of dead cells stained in red using
the ethidium homodimers dye.
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(Day3)

195
(Day3)

195+Hep
(Day3)

RT
(Day5)

RT+Hep
(Day5)

195
(Day5)

195+Hep
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Figure 38: Live/ Dead assay showing MSC attachment and viability on day 3 and 5 of
culture for chitosan fibers with different stiffness values, red-dead cells and green-live
cells
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8.3.2 Cytoskeleton Organization in MSCs Cultured on Mechanically Improved
Chitosan Fibers
The extent of cell spreading and cytoskeleton organization in MSCs cultured on
mechanically improved chitosan fibers were analyzed by fluorescent staining for actin
fibers. Figure 39 shows the actin fibers in MSCs when cultured on chitosan fibers dried
at room temperature, chitosan fibers dried at room temperature and immobilized with
heparin, chitosan fibers dried at 195 °C and MSCs cultur ed on a tissue culture plate.
Actin fibers present in MSCs cultured on all chitosan fibers were fairly organized
indicating a significant degree of cells spreading. Actin fibers seemed to be parallel to
the plane of the chitosan fiber, while actin fibers in MSCs cultured on tissue culture plate
were relatively disorganized. However, it is also worth mentioning that it was hard to
obtain fluorescent images of MSCs cytoskeleton of fibers dried at room temperature and
immobilized with heparin due to the fluorescence of the fibers. The arrow in Figure 39 C
points to a fluorescent fiber. Additionally, staining nucleus with DAPI was also hard to
be shown as fibers were also fluorescent. It’s likely that the high crystallinity of chitosan
fibers causes fibers to absorb the dye to be fluorescent. It was also clear that chitosan
fibers were fluorescent in Figure 38 during the Calcein AM assay which supports they
absorbance of chitosan fibers to the fluorescent dye.
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A

C

B

D

Figure 39: Cytoskeleton organization in MSCs on day 9 of culture when cultured on (A)
Fibers dried at RT, (B) fibers dried at RT and Immobilized with Heparin, (C) Fibers
annealed at 195 °C, arrow points to fluorescent chitosan fiber and (D) MSCs cultured on
Tissue culture plate, red: f-actin, blue: nucleus, Objective 20X.
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8.4

Discussion
For anchorage dependent cells like MSCs, the adhesion to the culture surface is

important for inducing several intracellular processes that control important cellular
events such as proliferation, differentiation and cell death. The signal transduction of the
cell-matrix interaction has been recently shown to influence the differentiation of MSCs
into SMCs (Suzuki et al., 2010). However, in the experiments outlined above, the
differentiation of MSCs into SMC was not confirmed with SMC differentiation marker
due to the fact that these cells are already differentiated into SMC. As discussed in the
previous chapter and confirmed by the results, MSCs showed similar characteristics to
SMC when cultured in culture medium supplemented with 10% FBS. So, it is expected
that MSCs cultured on fibers possess similar characteristics to SMC.
The main scope of this study was to test the biocompatibility of these
mechanically improved chitosan fibers and also to evaluate the effect of fiber stiffness
on MSCs proliferation, attachment and cytoskeleton organization. It was demonstrated
clearly that mechanically improved chitosan fibers supported MSCs attachment,
spreading and viability regardless of fiber stiffness. Moreover, it was feasible to
correlate fiber stiffness with cell proliferation. It was shown clearly that fiber with highest
stiffness yielded the highest MSCs proliferation. It was demonstrated previously that
matrix stiffness determines the fate of MSCs (Engler et al., 2006) and here it was
demonstrated that matrix stiffness significantly affects cell proliferation and cytoskeleton
organization. It was shown before that increasing chitosan membrane thickness
improved serum protein adhesion onto the membranes due to the increase in
membrane crystallinity (Uygun et al., 2010). Moreover, it was shown that chitosan
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membranes with highest thickness improved MSCs proliferation. In proliferation assay
results shown in Figure 37, the proliferation rate correlated to the fibers stiffness which
is correlated to the crystallinity of the fibers. As a result, a fiber with high stiffness has an
organized crystalline structure and tends to bind more serum proteins which ultimately
improve cell attachment and proliferation.
It was also demonstrated that heparin plays a key role in modulating growth
factors and binding proteins. Chitosan fibers immobilized with heparin had lower
stiffness values compared to unmodified fibers, yet MSCs proliferation was comparable
to chitosan fibers with higher stiffness values.

8.5

Conclusions and Future Work
In this chapter, the effect of fiber stiffness on MSCs attachment, cytoskeleton

organization and proliferation was clearly demonstrated. Moreover, the biocompatibility
of mechanically improved chitosan fibers produced through various chemical and
physical treatments were tested and showed that these treatments did not affect fiber
biocompatibility. The main purpose of improving the chitosan fibers mechanical
properties is to provide additional strength and stiffness to the heart valve scaffold upon
using the fiber-reinforcement approach. In addition to this purpose, the results in this
chapter showed that improving the scaffold mechanical properties will also improve the
cell proliferation within the scaffold to a further extent compared to the unmodified
scaffold.
It is recommended to study the effect of fiber stiffness on MSCs differentiation
into SMC or potentially to other heart cells by quantifying the amount of specific
differentiation protein or gene.
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Recent

research

has

demonstrated

a

strong correlation

between

the

differentiation profile of mesenchymal stem cells (MSCs) and scaffold stiffness.
Chitosan is being widely studied for tissue engineering applications due to its
biocompatibility and biodegradability. However, its use in load-bearing applications is
limited due to moderate to low mechanical properties. In this study, we investigated the
effectiveness of a fiber reinforcement method for enhancing the mechanical properties
of chitosan scaffolds. Chitosan fibers were fabricated using a solution extrusion and
neutralization method and incorporated into porous chitosan scaffolds. The effects of
different fiber/scaffold mass ratios, fiber mechanical properties and fiber lengths on
scaffold mechanical properties were studied. The results showed that incorporating
fibers improved scaffold strength and stiffness in proportion to the fiber/scaffold mass
ratio. A fiber-reinforced heart valve leaflet scaffold achieved strength values comparable
to the radial values of human pulmonary and aortic valves. Additionally, the effects of
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shorter fibers (2 mm) were found to be up to 3-fold greater than longer fibers (10 mm).
Despite this reduction in fiber mechanical properties caused by heparin crosslinking, the
heparin-modified fibers still improved the mechanical properties of the reinforced
scaffolds, but to a lesser extent than the unmodified fibers. The results demonstrate that
chitosan fiber-reinforcement can be used to generate tissue-matching mechanical
properties in porous chitosan scaffolds and that fiber length and mechanical properties
are important parameters in defining the degree of mechanical improvement. We further
studied various chemical and physical treatments to improve the mechanical properties
of chitosan fibers. With combination of chemical and physical treatments, fiber stiffness
improved 40fold compared to unmodified fibers. We also isolated ovine bone marrowderived MSCs and evaluated their utility for cardiovascular tissue engineering
applications. Moreover, we evaluated the effect of various glycosaminoglycans (GAGs)
on MSCs morphology and proliferation. Lastly, we studied the effect of stiffness of
mechanically improved chitosan fibers on MSCs viability, attachment and proliferation.
Results showed that MSCs proliferation improved in proportion to fiber stiffness.
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